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Chapter 1: Introduction 
Synopsis 
In 2017, the United States remains in the midst of what has been named 
the Opioid Epidemic, characterized by drug overdoses surpassing automobile 
accidents as the leading cause of death with a majority of these overdose deaths 
involving opioids (Wilson-Poe and Morón 2017). The Center for Disease Control 
and Prevention (CDC) responded to the rise of opioid abuse, overdose, addiction, 
and misuse by writing and releasing a set of opioid prescribing guidelines for the 
treatment of chronic non-cancer pain (Van Demark, Chang and Heinemann 
2016). However, these prescribing guidelines present challenges to physicians 
and patients seeking to maintain the use of opioids in a safe and controlled 
manner, leaving patients with few analgesic options to control chronic pain 
(Kroenke and Cheville 2017). While the solution for this situation must be multi-
faceted, the work presented in this thesis will focus on an understanding of the 
development and maintenance of chronic neuropathic pain and effective non-
opioid analgesics.  
 
Prevalence of Pain   
 Pain, as defined by the International Association for the Study of Pain 
(IASP), is an “unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage (1986).” 
Estimates of pain in America are as high as 126.1 million adults experiencing 
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some form of pain within the previous three months, and 25.3 million adults 
suffering from chronic pain, while 23.4 million experiences a large amount of pain 
(Nahin 2015).  Patients with the highest levels of pain use more health care, 
suffer more disability, and have a worse health status than those with lesser or 
no pain. Internationally, the rates of chronic pain in developed countries (37.3%) 
and developing countries (41.1%) demonstrate the vast population of chronic 
pain patients (Tsang et al. 2008). Pain presents in higher rates among women 
and the elderly and is associated with depression-anxiety spectrum disorders, but 
the majority of individuals with self-reported chronic pain do not qualify as 
presenting with depression or anxiety disorders (Tsang et al. 2008).  
 
Pain of Neuropathic Origin 
 Neuropathic pain is a pain class characterized by lesion or dysfunction of 
the central nervous system (CNS) from direct nerve or spinal cord injury, 
originating from diseases such as diabetes, stroke, or multiple sclerosis 
(Colombo, Annovazzi and Comi 2006).  While it remains clinically difficult to 
classify and evaluate pain etiology in patients (Steingrímsdóttir et al. 2017), 
around 9.8% of the population of pain patients suffer from pain of neuropathic 
origin (Yawn et al. 2009).   
Pain of neuropathic origin is traditionally thought to be responsive to 
anticonvulsant therapy (Tremont-Lukats, Megeff and Backonja 2000, BLOM 
1962), with gabapentin, carbamazepine and phenytoin showing efficacy at 
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relieving diabetic neuropathy and trigeminal neuralgia (Jensen and Larson 2001, 
Jensen 2002). Opioids are accepted as a class of treatments for neuropathic 
pain as long as an acceptable side-effect profile is maintained (Colombo et al. 
2006). Mu opioid receptor (MOR) agonist medications (Jones, Lawson and 
Backonja 2016) are thought to be effective in human neuropathic pain when 
given in sufficient doses and/or in combination with adjuvants (Varrassi et al. 
2009).  However, their long-term use is still debated (Cooper et al. 2017) due to 
small trial sizes, small effect sizes, and a lack of well-controlled studies.  Recent 
meta-analyses (Derry et al. 2016, Gaskell et al. 2016, Stannard et al. 2016) have 
concluded that the evidence for opioid effectiveness under conditions of 
neuropathic pain is either moderately supportive or inconclusive due to the broad 
heterogeneity of neuropathic conditions comprising the clinical trials. Placebo-
controlled clinical trials of opioids in neuropathic pain are ethically contraindicated 
as a placebo arm would experience unrelieved neuropathic pain. This leads to 
innovative trial design such as of several doses of the same opioid therapy rather 
than a placebo control (Rowbotham et al. 2003).   
 
Animal Modeling of Chronic Pain  
 Human epidemiological studies aimed at understanding chronic pain face 
the challenge of concretely defining chronic pain.  A meta-analysis found that 
among 86 studies purporting to evaluate chronic pain, no studies employed 
exactly the same criteria to their sample population (Steingrímsdóttir et al. 2017). 
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A benefit of conducting chronic pain research in animal models is the ability to 
precisely control the nature of pain and experimental interventions applied (Mogil 
2009).  These studies are essential to finding and characterizing novel 
therapeutics capable of addressing the lack of safe and effective pain 
therapeutics (Barrett 2015).  Animal models are especially beneficial when 
evaluating therapeutics intended to be given on a chronic schedule at 
determining the safety and early stage toxicity of new chemical entities 
(McGonigle and Ruggeri 2014).  In an effort to directly compare the results 
across all of the studies presented in this thesis, I have used a well-characterized 
and extensively used model of chronic neuropathic pain as developed by 
Decosterd and Woolf (Decosterd and Woolf 2000) in all of the pain studies 
presented in this thesis in an effort to tightly control the model, allowing for direct 
comparisons between each pharmacological tool used.  
 
NMDA Modulation to Alleviate Neuropathic Pain  
 N-methyl-D-aspartate receptor (NMDAR) antagonism has long been 
investigated as a therapeutic avenue in the treatment and control of neuropathic 
pain in both human- and animal-based studies (Sang 2000, Collins et al. 2010, 
Aiyer et al. 2017) due to this receptor’s role in persistent pain pathways 
(Bleakman, Alt and Nisenbaum 2006) including pain arising from damage to 
peripheral or central nerves.  Glutamatergic signaling is altered in multiple ways 
along nociceptive pathways in chronic pain states including an increase in the 
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release of glutamate in the dorsal horn of the spinal cord from primary afferent 
terminals (Chen et al. 2009), a decrease in the clearance rate of glutamate from 
the synaptic cleft (Sung, Lim and Mao 2003), and an increase in the number of 
NMDA receptors (Salter and Pitcher 2012). A plethora of NMDAR antagonists 
have been studied in clinical trials of chronic neuropathic pain including ketamine, 
methadone, memantine, amantadine, dextromethorphan, carbamazepine, 
phenytoin, and valproic acid which represent action at allosteric binding sites, 
subtypes 2A through 2D, non-competitive binding, and pre-synaptic NMDA 
inhibition of glutamate release (Aiyer et al. 2017). The most consistently 
efficacious therapeutic NMDA antagonist, intravenous ketamine, is not FDA 
approved for the treatment of neuropathic pain conditions, and drug-induced liver 
injury or altered liver function has been reported in patients receiving ketamine 
treatment (Noppers et al. 2011).   
 While NMDA antagonism is an attractive pharmacological approach, 
physiological NMDA activity is essential for the continuity of normal function. As 
such, pharmacological agents that inhibit broad spectrum NMDA activity have 
impactful clinical side effects including psychotic symptoms, memory impairment, 
and motor impairment (Olney 1994, Lipton 2004, Neznanova et al. 2000). These 
findings have led to the search for an NMDA antagonist that preferentially and 
site-selectively inhibits excessive NMDA activity without disrupting normal, 
physiological function.  
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Agmatine: A Novel NMDA Antagonist  
 Agmatine was first purified from herring sperm and characterized by Noble 
Laureate Albrecht Kossel in 1910 (Kossel 1910), but was only investigated 
sparingly until 1994 (Li et al. 1994) due to the erroneous assumption that 
agmatine was not synthesized in mammals (Tabor and Tabor 1984).  Agmatine 
is synthesized by arginine decarboxylase (ADC) in both mammalian and plant 
tissue; the sequence of human ADC is distinct from other forms (Zhu et al. 2004). 
The degradation of agmatine to putrescine and urea occurs mainly via 
agmatinase-mediated hydrolysis (Sastre et al. 1996). ADC and agmatinease 
respectively constitute the main synthetic and degradative pathways for 
endogenous agmatine.  
Early studies of agmatine elucidated its efficacy at antagonizing NMDARs 
in cultured rat hippocampal neurons (Yang and Reis 1999).  Putrescine was 
ineffective at reproducing this block, suggesting that the guanidine is the active 
moiety required for agmatine’s block of NMDAR. We have recently expanded this 
line of investigation to interrogate the subunit requirements for agmatine’s 
inhibition of NMDAR currents through the use of GluN2B-floxed mice and whole 
cell patch clamp electrophysiology (Wataaja, in preparation). This area of 
research will be discussed in depth in Chapter 4 of this thesis.  
Functionally, agmatine has demonstrated efficacy at and inhibiting 
glutamate-induced neurotoxicity through NMDA antagonism in cultured cerebellar 
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granule cells (Olmos et al. 1999).  In vivo, many studies have demonstrated 
agmatine’s efficacy at either direct analgesia in models of neuropathic pain 
(Karadag et al. 2003, Kotagale et al. 2013, Fairbanks et al. 2000) or as an 
adjunct to modulate opioid analgesia (Kolesnikov, Jain and Pasternak 1996, Su, 
Li and Qin 2003, Regunathan 2006). The foundation of these studies indicates 
that agmatine is a viable candidate for the analgesic relief of chronic, neuropathic 
pain but more work is needed to understand it’s side effect profile and it’s efficacy 
as compared to clinically relevant analgesics.  This work will be presented in 
Chapter 2.  
 
AAV Gene Therapy to Deliver Chronic Therapeutics 
 Gene therapy is an emerging strategy for providing long-term relief for 
chronic pain syndromes (Guedon et al. 2015). The adeno-associated viral vector 
offers very desirable traits for application to gene therapy, and recently became 
the first vector system approved for clinical applications (Bryant et al. 2013).  The 
parent virons do not replicate and are considered to be non-pathogenic, reducing 
the possibility of a severe immune reaction that could be harmful or deadly for a 
patient (Mingozzi and Buning 2015).  This family of vectors also has an extended 
period of expression, having been seen to express for up to a decade (Buchlis et 
al. 2012).  This feature makes them desirable to apply to a disease state such as 
neuropathic pain that requires continuous modulation.  AAV vectors also come in 
a variety of serotypes with different patterns of expression. Interestingly, only a 
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small subset of these serotypes are able to cross the BBB (Zincarelli et al. 2008).  
It has also been noted that the route of delivery of the vector can have an impact 
on the pattern of expression (Thierry et al. 1995).  For these reasons, AAV 
therapy provides the ability to customize expression to areas of interest via 
multiple strategies (Mingozzi and Buning 2015). In Chapter 3, I will describe our 
use of two AAV serotypes, AAV5 and AAV9, to deliver arginine decarboxylase to 
the central nervous system, the subsequent increase in endogenous agmatine, 
and the attenuation of neuropathic pain behaviors. 
 
AAV Targeting via Differing Serotype Expression 
All AAV serotypes have the same genome size and organization.  They 
are all single-stranded DNA parvoviruses of the genus Dependovirus. Twelve 
human serotypes have been discovered (Daya and Berns 2008), numbered 
AAV1-AAV12.   The serotype of each AAV vector will have an impact on where 
the vector expresses.  The injection route, as well as the model used, will also 
show different patterns of expression.  The following sections highlight the 
differential expression achieved through different AAV serotypes, as well as the 
injection route used to achieve that pattern of expression.  This information is 
critical for the design and implementation of targeted gene therapy to decrease 
off-target effects.  
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AAV2  
 AAV2 was the first serotype ever utilized for gene transfer with initial 
publication in 1984 (Hermonat and Muzyczka 1984).  In a systematic analysis of 
AAV serotypes 1-9 in a mouse model utilizing tail vein injection, Rabinowitz and 
colleagues characterized AAV2 as having low expression and slow onset of 
expression (Zincarelli et al. 2008).  In a more recent analysis utilizing mouse as 
well as marmoset and macaque models, AAV2 was found to have a distinct 
pattern of expression compared to 1, 5, 8, and 9 (Watakabe et al. 2014).  While 
all serotypes were able to transduce cortical cells in the marmoset cerebral 
cortex, AAV2 had a noticeably smaller spread and a neural tropism as compared 
to the robust glial expression of the other serotypes, with these results being 
confirmed in the mouse and macaque models.     
AAV2 does not cross the BBB and enter the CNS following facial vein 
injection in a neonatal mouse (Zhang et al. 2011).  A team of researchers, 
however, was able to develop a technique of inducing opening of the BBB by 
ultrasound and subsequently showed activity of the AAV2 virus in the rat brain 
following peripheral delivery(Alonso et al. 2014).  A consideration needs to be 
made from a therapeutic and clinical standpoint whether it would be more 
beneficial for the patient to undergo this stimulation in order to open the BBB and 
allow the vector to enter the CNS or if the therapy should be developed with a 
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different serotype that can cross the barrier naturally if the area to be targeted is 
within the CNS.   
AAV5  
AAV5 is characterized by low expression as well as a slow onset 
compared to vectors 1-4 and 6-9 after tail vein injection in mail mice (Zincarelli et 
al. 2008).  Under a general CMV promoter in a marmoset cerebral cortex model, 
as well as mouse and macaque, AAV5 was found to transduce mostly glial cells 
but was able to transduce neurons when placed under a CaMKII promoter 
(Watakabe et al. 2014).   
In study aimed at elucidating various vector’s ability to cross the BBB, it 
was noted that AAV5 did not enter the CNS following a facial vein injection of 
virus in a neonatal mouse (Zhang et al. 2011).  However, when delivered 
intrathecally, AAV5 was able to transduce a wide subset of the CNS, including 
hindbrain, isolated neurons and astrocytes in the midbrain, as well as rostrally to 
the olfactory bulb.  This pattern of expression potentially indicates that AAV5 is 
able to spread through the movement of cerebrospinal fluid (CSF) if delivered 
within the CNS (Schuster et al. 2014a). The use of intrathecally delivered AAV5 is 
further discussed in Chapter 3.   
 
AAV9  
 AAV9 contains the inherent ability to pass through the BBB, a traditionally 
difficult to penetrate barrier (Byrne et al. 2015).  Before that, it was known that the 
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capsid had a high affinity for the heart following IV injection in adult mice (Pacak 
et al. 2008).   While AAV2 and AAV5 were found to have low expression in a 
mouse model following tail vein injection, AAV9 was characterized to have both a 
rapid onset of expression as well as high expression as determined by 
bioluminescence imaging (Zincarelli et al. 2008). 
 Additionally, systematic studies of AAV9 show that its efficacy at crossing 
the BBB is in part determined by the age of the subject and the stage of 
maturation of their BBB.  Following IV injection of AAV9 at various ages, it was 
seen that the resulting expression was more efficient in neonatal than adult mice 
(Foust et al. 2009).  Neonatal mice showed extensive transduction of neurons 
throughout the brain whereas adult mice showed transduction limited to mostly 
astrocytes and small proportion of neurons.    
 It is important to consider the route of administration when evaluating 
distribution of AAV9, despite its ability to cross the BBB.  In a study directly 
comparing intravenous and intrathecal injection in a mouse model of AAV9, it 
was noted that intrathecal delivery of vector resulted in increased efficiency of 
transducing sensory neurons and the central nervous system (CNS) (Schuster et 
al. 2014b).  The vector delivered intravenously was able to cross the BBB and 
express in a selection of isolated neurons and astrocytes, but intrathecal delivery 
resulted in a more intense and more widespread distribution.  Also of note from 
this study was the observation that intrathecal delivery of AAV9 vector resulted in 
transduction of peripheral tissues, signifying that the vector was able to 
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redistribute into the systemic circulation from the subarachnoid space.  
Intrathecal AAV9 is further discussed in Chapter 3.  
 
AAV Promoter and Enhancer Sequences 
In the previous section describing serotype, a majority of the studies were 
conducted with vectors containing a cytomegalovirus (CMV) promoter.  This 
promoter is commonly used as a general promoter/enhancer of expression with 
the thought that it will provide a robust and long-lasting expression, (McCown et 
al. 1996).  More recently, studies have been published characterizing the 
expression and distribution of this promoter compared to other general promoters 
as well as limited promoters (for example, neuron-specific).  The following 
sections will focus on these different promoter/enhancer sequences. 
 
Constitutive CMV Promoter  
  The cytomegalovirus (CMV) promoter is the most widely used promoter in 
viral vector design, as it leads to a relatively stable expression and broad 
distribution.  This was systematically tested by Damdindorj et al. (Damdindorj et 
al. 2014) in a study comparing CMV to 5 other constitutive promoters in a variety 
of cell lines.  In this study, they observed that the CMV promoter drove the 
highest level of GFP expression across the different cell lines and maintained 
expression for the 8 weeks of the study.  However, the same study found that 
using a CMV promoter to drive gene editing led to the lowest efficiency among 
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the compared promoters.  It is important to note that this study was conducted 
using all cancerous cell lines, and that further study in either primary culture or 
animal models would be beneficial.    
 Further advancements in constitutive promoter design have been 
suggested and designed, with hybrid CMV-based promoters gaining interest in 
the field (Fitzsimons, Bland and During 2002).  These modifications are intended 
to enhance gene expression as well as stabilize gene expression, hopefully 
making gene therapy in chronic diseases like chronic neuropathic pain a more 
viable option as expression was seen for up to a year.   
 CMV can also be used as an enhancer, and has traditionally been 
combined with a chicken-beta-actin promoter (Xu et al. 2001).  In one initial 
study, this CMV-beta-actin combination resulted in an 137-fold increase in 
expression compared to a CMV promoter/enhancer construct when studied in 
neonatal mice.  Another study utilizing this promoter/enhancer combination 
showed a rapid and robust response in a mouse model of lysosomal storage 
disease, another disease requiring extended therapy (Daly et al. 1999).  The 
injection of vector occurred in neonatal mice and was detected 2 weeks after 
birth, and no reduction in expression was noted for 16 weeks.   
 
Additional Constitutive Promoters  
While a study comparing the CMV promoter to various constitutive 
promoters found CMV to have the highest level of GFP expression, CMV was not 
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the most efficient at driving gene editing, a common application for AAV gene 
therapy.  The constitutive promoters human beta-actin (hACTB) and human 
elongation factor-1alpha (hEF1a) were especially notable in the DLD-1 cell line 
(Damdindorj et al. 2014).  In the previously mentioned study comparing CMV-
beta-actin to CMV alone, elongation factor 1-alpha (EF1-alpha) was also 
analyzed.  It was seen that while the EF1-alpha promoter had higher expression 
than CMV alone in vivo, CMV-beta-actin was significantly higher than both of the 
previous constructs (Xu et al. 2001).   
 
Neuron-Specific Promoters 
 It is common that a therapy is only needed in neuronal cells, creating the 
needs for neuron-specific expression.  Human synapsin 1 (hSYN1) can be 
employed for this purpose.  It has been seen that an AAV9 serotype in 
combination with an hSYN1 promoter achieves widespread, due to the tropism of 
AAV9, neuron-specific expression following intracerebroventricular (i.c.v.) 
delivery in neonatal mice (McLean et al. 2014).   In a similar study conducted in a 
rat model, this neuron-specific expression was seen to be long-term if the vector 
was given at the appropriate dose (Kugler, Kilic and Bahr 2003).   This study 
compared hSYN1 to another neuron-specific promoter, namely neuron-specific 
enolase (NSE).  They found that NSE was not completely neuron-specific but 
rather also expressed in glial cells.  It also had a lower level of transcriptional 
targeting compared to hSYN1.   
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 A third neuron-specific promoter, calcium/calmodulin-dependent protein 
kinase II (CaMKII), has been shown to transduce inhibitory somatosensory 
cortical neurons in a mouse model when packaged with AAV2 (Nathanson et al. 
2009).  It is important to note that virus was directly injected into the 
somatosensory cortex for this experiment, as AAV2 is not expected to cross the 
BBB.  However, in a study utilizing a marmoset model, CaMKII was delivered 
also to the somatosensory area using serotypes 1, 2, 5, 8, and 9.  This study also 
injected virus into both male and female mice, as well as macaque.  This second 
study examining CaMKII did not observe the selection for inhibitory 
somatosensory cortical neurons but rather saw that a majority of neurons were 
transduced (Watakabe et al. 2014).   
 
Thesis Preview 
Based on this scientific foundation, I sought to determine the efficacy and 
potential side effects of exogenous (small molecule) and endogenous (viral 
vector) approaches to delivering agmatine in a model of chronic neuropathic 
pain. I sought to determine if an increase of agmatine would prevent or reverse 
the development of hyperalgesia in a spared nerve injury model of neuropathic 
pain, as well as evaluate motor function and other behaviors to support 
translation of agmatine into a clinical setting. Finally, I sought to evaluate 
agmatine’s signaling pathway using a GluN2B-floxed conditional knockout 
mouse.   
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Thesis Objectives 
Effective treatment for chronic pain patients remains an area of largely 
unmet need. However, chronic pain patients receiving traditional opioid therapy 
are consistently surrounded by the potential risks and social stigmas of opioid 
dependence, misuse, and addiction. These concerns are heightened in the face 
of the expanding opioid epidemic. The need for new, non-opioidergic 
therapeutics for management of the large population of chronic patients is widely 
recognized. Agmatine, also known as decarboxylated arginine, is an endogenous 
small molecule that has been shown to modulate maladaptive neuroplasticity that 
underlies the experience of chronic pain. Agmatine has been established to meet 
the criteria of acting as a neurotransmitter including synthesis in neurons (Wang 
et al. 2014), release from nerve terminals (Goracke-Postle et al. 2007), and 
binding to post-synaptic receptors (Gibson et al. 2002, Yang and Reis 1999). We 
have previously demonstrated the efficacy of exogenously delivered agmatine in 
reversing chronic pain behaviors in models of neuropathic pain. Targeting 
primary sensory neurons through gene vectors such as serotypes of the adeno-
associated virus has recently been identified as a powerful emerging strategy to 
treat chronic, intractable pain (Pleticha, Maus and Beutler 2016). Gene therapy 
has been approved for market use in Europe and the United States, making it a 
viable tool for translation from bench side to clinic. To this end, a viral vector 
encoding the synthetic enzyme for agmatine, namely arginine decarboxylase was 
developed. It has been shown that intrathecally injected viral vector particles 
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distribute to sites of interest for chronic pain (Vulchanova et al. 2010, Schuster et 
al. 2014a, Schuster et al. 2014b). 
The primary objective of my thesis work has been to expand both the 
application and mechanistic understanding of agmatine as a non-opioidergic 
therapeutic in the treatment of chronic pain. The central hypothesis of this work is 
that enhanced expression of arginine decarboxylase in nociceptive pathways 
results in long-term reduction of neuropathic pain due to agmatine production and 
agmatine’s antagonism of the NMDA receptor. The rationale for this research 
was that delivery of a gene therapy to enhance agmatine’s inhibition of NMDA 
signaling would be a viable, long term solution for management of chronic 
pain.  Through the next sections I will expand upon the dual public health crises 
of chronic pain and prescription opioid abuse. These call for new, non-opioid 
therapeutic approaches for chronic pain, leading to the therapeutic development 
of agmatine as an NMDA receptor antagonist.  
 
Chapter 2 
In this thesis, I will report my work utilizing these ideas of NMDA 
modulation via agmatine. In Chapter 2, I present a set of experiments intended to 
pursue Specific Aim 1: 
 
Specific Aim 1: Compare the pharmacological effects of agmatine to its 
primary metabolite and gold standard NMDA receptor antagonists.   
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The experiments developed to address Specific Aim 1 assessed the effects of 
NMDA antagonism in chronic neuropathic pain by agmatine, its primary 
metabolite putrescine, and several gold standard NMDA receptor antagonists.  
These comparative studies were essential to expand upon the prior knowledge 
contributed by our research group regarding the effects of exogenously delivered 
agmatine on chronic neuropathic pain.  Specifically, we sought to understand the 
effects of agmatine compared to its primary metabolite, putrescine, the primary 
gold standard non-selective NMDA receptor antagonist, MK-801, and the primary 
gold-standard GluN2B subunit-selective NMDA receptor antagonist, ifenprodil. 
Both prevention of the development of neuropathic pain as well as the reversal of 
established pain by agmatine is presented. Additionally, we were able to define 
an optimal drug delivery schedule of agmatine as well as determine the 
effectiveness of agmatine treatment in the maintenance phase of established 
neuropathic pain. These experiments provided essential foundation which 
informed and enabled the pursuit of Specific Aims 2A, 2B, and 3 of the thesis 
proposal.  
 
Chapter 3 
Based on our preliminary data, I hypothesized that delivery of an adeno-
associated viral vector that overexpresses the enzyme for conversion of L-
arginine to agmatine would be effective at preventing or reversing chronic 
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neuropathic pain. This hypothesis was addressed through delivery of a vector to 
overexpress the synthetic enzyme for agmatine in a rodent model of neuropathic 
pain.  Tactile sensory and motor function behavioral testing was performed as 
well as immunohistochemical assessment to demonstrate anatomical distribution 
of a reporter gene (green fluorescent protein) throughout the central nervous 
system.  
In Chapter 3, I present extensive behavioral characterization of the use of 
agmatine-based gene therapy to prevent or reverse chronic neuropathic pain in 
both rat and mouse models. These experiments were designed to address 
Specific Aim 2A: 
 
Specific Aim 2A: Determine the ability of overexpression of arginine 
decarboxylase to prevent and reverse chronic pain behaviors 
 
The experiments developed to address Specific Aim 2A assessed the 
effects of intrathecal delivery of an adeno-associated viral vector that carried the 
gene for arginine decarboxylase on neuropathic pain. We observed that in both 
rat and mouse, pre-treatment with this viral vector construct reversed neuropathic 
pain.   We also observed that post-treatment of the viral vector also reversed 
neuropathic pain in mice. We used an immunoneutralization approach to 
demonstrate that both pharmacological outcomes are dependent on spinal 
agmatine.   
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Based on our preliminary data collected from pursuit of Specific Aim 2A, I 
also hypothesized that delivery of this same AAV vector designed to express 
arginine decarboxylase (hADC, the synthetic enzyme for agmatine) would be 
effective at reversing and preventing the development of chronic pain with 
efficacy lasting up to a year following injection. I pursued a second aim to 
address this hypothesis: 
 
Specific Aim 2B: Determine the duration and therapeutic window of AAV-
hADC treatment 
 
To assess the duration of AAV-hADC mediated analgesic efficacy after nerve 
injury, we studied various cohorts of mice for varying durations of time out to a 
year post-injury.  To assess the therapeutic window of efficacy after nerve injury, 
we studied various cohorts of mice that were injected with AAV-hADC either two 
weeks after nerve injury or as late as nine months after nerve injury. These 
experiments demonstrated that the duration of action of our gene therapeutic as 
well as the window of efficacy after injury where the therapeutic is still effective at 
reversing behavioral hypersensitivity is as late as nine months post-injury and at 
least 11 post-injection.  
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Chapter 4 
In Chapter 4, I evaluated a potential signaling pathway for agmatine by 
utilizing a conditional genetic knockdown of the GluN2B subunit of the NMDA 
receptor. This line of research emerged from the work represented in Chapter 2 
and 3 and previous literature. Our working hypothesis emerged that agmatine 
requires the GluN2B subunit of the NMDA receptor for reversal of behavioral 
hyperalgesia.  To address this hypothesis, I pursued the following Specific Aim: 
 
Specific Aim 3: Determine the NMDA receptor subunit target of agmatine in 
vivo. 
 
I addressed this hypothesis by delivering exogenous agmatine to either 
transgenic GluN2B-deficient or wildtype mice under conditions of nerve injury and 
evaluated the resulting anti-hyperalgesia. In Chapter 4, I describe our 
development of the knockdown, as well as behavioral data examining agmatine’s 
efficacy in both knockdown and wildtype animals in models of chronic 
neuropathic pain as well as opioid tolerance.  
 
Summary 
 After conducting my thesis research, I have completed several key 
objectives.  I have evaluated the behavioral impact of exogenous delivery of 
agmatine and various NMDA inhibitors in chronic neuropathic pain. Additionally, I 
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have systematically evaluated the impact of AAV gene therapy delivering the 
synthetic enzyme for agmatine, arginine decarboxylase, in a model of chronic 
neuropathic pain. Lastly, I evaluated the necessity for the GluN2B subunit of the 
NMDA receptor for agmatine’s efficacy in reversing hyperalgesia in a model of 
chronic neuropathic pain as well as preventing the development of morphine 
tolerance.  
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Chapter 2: Prevention and Reversal of Chronic  
Neuropathic Pain via Agmatine 
 
Synopsis 
Agmatine, decarboxylated L-arginine, is endogenously synthesized by 
arginine decarboxylase and has shown to effectively inhibit expression of 
neuropathic and inflammatory pain when delivered either centrally or 
systemically.  In this chapter, I will show pharmacological and behavioral 
confirmation of agmatine’s efficacy in preventing and reversing both evoked and 
non-evoked manifestations of neuropathic pain, as well as a direct comparison to 
the clinically used standard of analgesia, morphine.  These data support the 
hypothesis that agmatine is an effective analgesic and a viable candidate for 
clinical translation.  
 
 
 
 
 
 
 
(C.P planned and conducted the experiments and behavioral analysis.  K.K. 
conducted experiments.  C.A.F and G.W. contributed to analysis and editing.)  
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Introduction 
 Agmatine was first discovered in 1910 by the Nobel laureate Albrecht 
Kossel (Kossel 1910).  Agmatine, the decarboxylated form of L-arginine, is 
endogenously synthesized in mammals by arginine decarboxylase (Li et al. 
1994).  Agmatine meets many of the criteria of acting as a 
neurotransmitter/neuromodulator including synthesis in neurons (Wang et al. 
2014), release from nerve terminals (Goracke-Postle et al. 2007), and binding to 
post-synaptic receptors (Gibson et al. 2002, Yang and Reis 1999).  This small 
molecule is an inhibitor of the N-methyl-D-aspartate receptor (Yang and Reis 
1999), a receptor found on nociceptive neurons that relay pain signals from the 
periphery, through the spinal cord and into the brain for sensory processing.  This 
action through the NMDA receptor rather than traditional opioid receptors makes 
agmatine a viable and promising therapeutic target, allowing for modulation of 
pain sensation without established concerns surrounding the opioidergic system 
(Fairbanks et al. 2000).  In this chapter, I will assess agmatine’s efficacy, duration 
of action, and role in maladaptive neuroplasticity prior to or following the 
development of peripheral neuropathic pain.  
 
Spared Nerve Injury Model of Neuropathic Pain  
 Neuropathic pain is an umbrella term used to describe pain originating 
from lesion or dysfunction of normal sensory pathways (Jensen et al. 2001).  This 
dysfunction may arise from disorders such as diabetes, malignant diseases, 
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physical trauma, vitamin deficiencies, and immune deficiencies (Woolf and 
Mannion 1999).  Clinically, neuropathic pain is characterized by both 
spontaneous pain as well as stimulus-evoked pain (Marchettini et al. 2006).  We 
have chosen the spared nerve injury (SNI) model of rodent neuropathic pain 
(Decosterd and Woolf 2000) to represent these clinical symptoms.  In this model, 
the sciatic nerve is exposed and its three branches (tibial, peroneal, and sural) 
are identified.  Both the tibial and peroneal branches are ligated and cut while the 
sural branch is spared.  This ligation results in a marked increase in mechanical 
hypersensitivity in the lateral portion of the paw, the area innervated by the sural 
nerve.  Induction of hypersensitivity occurs within the first day post-surgery and 
results in a long-lasting hypersensitivity that is not likely to resolve.  Additionally, 
all animals that receive this surgery develop the pain phenotype, indicating a 
robust model.  
 
Morphine’s Efficacy in Neuropathic Pain 
Morphine remains one of the most studied and characterized clinically-
available analgesics (Corbett et al. 2006), and is listed by the World Health 
Organization as an essential medicine for post-operative, analgesic and palliative 
care (Organization 2011).  While morphine has clinically shown efficacy for short 
term reversal of pain of neuropathic origin (Wang et al. 2017),  recent analysis 
has shown little to no support for the claim that morphine given alone is an 
effective chronic treatment for chronic, neuropathic pain (Cooper et al. 2017a), 
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with some studies even reporting a trend towards a decrease in physical function 
and an increase in disability following chronic morphine use (Bostick et al. 2015).  
However, many pre-clinical studies using animal models of chronic, neuropathic 
pain continue to report efficacy of morphine given alone in reversing pain 
behaviors (Smith et al. 2017).  Divergence between these findings may be due in 
part to the well-documented phenomena of opioid tolerance (decreased efficacy 
following repeated administration of the same drug) following chronic morphine 
treatment (Wilson-Poe, Jeong and Vaughan 2017, Elhabazi et al. 2014, Dighe et 
al. 2009).  In this chapter, I have included a control of centrally delivered 
morphine in early and late phase neuropathic pain in order to compare the 
efficacy, time to onset, and duration of effect of the well characterized morphine 
to agmatine, our experimental treatment.    
 
Evoked vs. Constitutive Pain  
 Evoked (reflexive) measures of pain behavior remain one of the most 
commonly used indicators of the presence and level of neuropathic pain in 
animal models.  These assays evaluate the level of behavioral pain responses 
following heat, cold, electrical or mechanical stimuli (Gregory et al. 2013).  While 
these tools remain useful, a major advancement in pain research has been the 
understanding of a variety of behavioral and physiological expressions of pain 
(Yaksh 2002) as a mechanism to evaluate new and novel pathways and 
therapeutics.  In models of muscular pain, analgesics restore impaired motor 
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function, indicating that part of the reduction in motor function is associated with 
sensory hypersensitivity rather than muscle dysfunction.  I extended these 
observations to evaluate motor performance under conditions of neuropathic pain 
and the impact of agmatine on motor performance in neuropathic mice.  To this 
end, I used the rotating rod (rotarod) assessment commonly used to evaluate 
motor impairment following drug administration.   
 
Materials & Methods 
Animals 
Male ICR-CD1 mice (21-24G, Harlan, Madison, Wisconsin) were housed 4 to a 
cage in a 12-hour light/dark cycle.  They were given free access to food and 
water in a temperature and humidity controlled environment.  All experiments 
were approved by the Institutional Animal Care and Use Committee of the 
University of Minnesota.   
 
Chemicals and Reagents 
 Agmatine sulfate, dizocilpine maleate ((+)- MK-801), ifenprodil, and 
putrescine dihydrochloride were purchased from Sigma-Aldrich (St. Louis, MO).  
All drugs were dissolved in 0.9% saline.  Anti-agmatine antiserum was generated 
in guinea pigs as previously described (Wade et al. 2009).   
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Intrathecal Injections 
All drugs were dissolved in sterile saline and delivered in 5-μl volumes via 
intrathecal injection in conscious mice (Hylden and Wilcox 1980).  Briefly, the 
mice were held by the iliac crest and a 30-gauge, 0.5-inch needle attached to a 
50-µL Luer-hub Hamilton syringe delivered 5 µL of injectate into the intrathecal 
space of the mice.  
 
Spared Nerve Injury 
Tactile hypersensitivity was induced using the spared nerve injury model 
described by Decosterd and Woolf (Decosterd, Allchorne and Woolf 2002).   
Subjects were placed under isoflurane anesthesia and the left sciatic nerve was 
exposed, along with its three terminal branches.  The common peroneal and tibial 
nerves were ligated with 5.0 silk suture.  The nerves were sectioned 2 mm distal 
to the ligation site.  The sural nerve remained uninjured.   
 
Tactile Hypersensitivity  
Mice were placed on a wire mesh grid under a glass enclosure and 
allowed to acclimate for 30 minutes prior to testing.  Hypersensitivity was tested 
by using an electronic von Frey device (Life Sciences, IITC).  The left and right 
hindpaws were stimulated by the tip of the stimulator with enough force to cause 
the mouse to withdraw its paw.  The amount of force required for withdrawal was 
recorded in grams.  Baseline responses before SNI were collected, and the 
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%MPE was calculated by the following formula: (Experimental Value-
Control)/(Cutoff-Control) X 100.  For the purpose of these experiments, the 
following measurements were used: (Post-Drug Threshold – Pre-Drug 
Threshold)/(Pre-Surgery Baseline Threshold – Pre-Drug Threshold) X 100.  
 
Motor Coordination 
Motor coordination was assessed via an accelerating rotarod (Ugo Basile, 
Carese, Italy).  After a training session, mice were given the opportunity to walk 
on an accelerating (4-40 rpm) rod for a maximum of 300 seconds.  We recorded 
and compared the latency to fall off of the rotarod between treatment groups.   
 
Statistical Analysis 
 All statistical analysis was considered significant at α ≤ 0.05.  Mechanical 
paw withdrawal thresholds collected by von Frey filament stimulation were 
analyzed by repeated measures ANOVA with Bonferroni post-hoc corrected 
analysis.  Motor coordination data were analyzed by one-way ANOVA.  
 
Results 
Agmatine Inhibits Injury-Induced Neuroplasticity  
The first goal of this study was to determine agmatine’s efficacy at 
reversing neuropathic pain behaviors as measured by von Frey threshold.  To 
address this question, we utilized the SNI model, a well-characterized model of 
	  	   37	  
neuropathic pain in rodents (Decosterd and Woolf, 2001).  Immediately prior to 
surgery, each mouse was injected intrathecally with a 5 microliter solution of 10 
nmol agmatine, as well as on alternating days following surgery (day 2, 4, and 6).  
Subjects were assessed for their von Frey thresholds prior to surgery and on 
alternating days after surgery (days 1, 3, 5, and 7) on both the injured (ipsilateral) 
and non-injured (contralateral) hindpaws.  Additional von Frey testing continued 
weekly for a maximum of 30 days following injury.  Mice that received intrathecal 
agmatine experienced significant attenuation of the development of neuropathic 
pain past the cessation of intrathecal agmatine injection.  These data are 
represented in Figure 1A. 
Additional cohorts were generated and tested in the same manner as the 
agmatine cohort, but with different pharmacological compounds.  Dizocilpine 
(MK-801), ifenprodil, and putrescine were all intrathecally delivered immediately 
prior to surgery as well as on days 2, 4 and 6 after injury.  Behavioral testing was 
conducted on days 1, 3, 5, and 7, as well as weekly until a maximum of 30 days 
following injury.  Intrathecal MK-801 inhibited the development of hypersensitivity 
following SNI.  Intrathecal ifenprodil showed reduced efficacy as compared to 
agmatine and MK-801, and putrescine was ineffective, displaying similar 
hypersensitivity to the saline controls.  These data are represented in Figure 1B-
D.  
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Agmatine Reverses Established Neuropathic Hypersensitivity 
 We sought to test the hypothesis that agmatine reverses already 
established hypersensitivity in the SNI model of neuropathic pain.  Mice were 
tested for their von Frey sensitivity thresholds prior to and following SNI.  Two 
weeks following injury, three groups of equal responding were selected and given 
saline control, 1 nmol agmatine or 10 nmol agmatine intrathecally for 4 injections 
on alternating days.  Behavioral testing was conducted every day following drug 
injection and up to 30 days following injury.  Intrathecal agmatine attenuated the 
expression of established neuropathic pain, but this attenuation did not persist 
following the cessation of injection as it did in Figure 1.  These data are 
represented in Figure 2.  
 
Morphine Reverses Neuropathic Hypersensitivity in a Dose-Dependent 
Manner 
 Opioid therapy remains the gold standard in treating clinically presented 
pain (Cooper et al. 2017b, Dosenovic et al. 2017).  As such, we sought to confirm 
and compare the efficacy of centrally delivered morphine at various doses (1, 3, 
and 10 nmol) in both the early (induction) and late (maintenance) phases of the 
establishment of chronic neuropathic pain.  To test for morphine’s early efficacy, 
animals were assessed for their uninjured von Frey thresholds and then given 
SNI.  On day 3 following injury, mice were assessed for their post-injury von Frey 
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thresholds on both the injured (ipsilateral) and non-injured (contralateral) 
hindpaws.  1 nmol morphine was intrathecally injected, followed by additional von 
Frey assessments at 30, 60, 90, 150, and 180 minutes post-injection.  This 
paradigm was repeated on day 4 (3nmol) and day 5 (10nmol).  These data are 
represented in Figure 3.  To assess for morphine’s efficacy in the maintenance 
phase of neuropathic pain, a second cohort of mice were assessed on days 14 (1 
nmol), 15 (3 nmol) and 16 (10nmol) post-injury.  Morphine displayed a dose-
dependent reversal of hypersensitivity following spared nerve injury in both 
induction and maintenance phases of neuropathic pain. These data are 
presented in Figure 3.  
 
Agmatine Reverses Neuropathic Hypersensitivity in a Dose-Dependent 
Manner 
We sought to confirm and compare the efficacy of systemically delivered 
agmatine at various doses (10, 30, 100 mg/kg) in both the early (induction) and 
late (maintenance) phases of the establishment of chronic neuropathic pain.  To 
test for agmatine’s early efficacy, animals were assessed for their uninjured von 
Frey thresholds and then given SNI.  On day 3 following injury, mice were 
assessed for their post-injury von Frey thresholds on both the injured (ipsilateral) 
and non-injured (contralateral) hindpaws.  10 mg/kg agmatine was intravenously 
injected, followed by additional von Frey assessments at 30, 60, 90, 150, and 
180 minutes post-injection.  This paradigm was repeated on day 4 (30 mg/kg) 
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and day 5 (100 mg/kg), and these data are represented in Figure 4.  To assess 
for agmatine’s efficacy in the maintenance phase of neuropathic pain, a second 
cohort of mice was assessed on days 14 (10 mg/kg), 15 (30 mg/kg) and 16 (100 
mg/kg) post-injury.  Agmatine displayed a dose-dependent reversal of 
hypersensitivity following spared nerve injury in both induction and maintenance 
phases of neuropathic pain.  
 
Agmatine Attenuates Non-Reflexive Pain Behaviors as Measured by Motor 
Performance 
In addition to reflexive (von Frey) behavioral testing, we sought to assess 
whether central delivery of agmatine attenuates non-reflexive expressions of 
neuropathic pain.  To this end, we performed SNI on male ICR mice.  Prior to 
injury and following injury, mice were assessed for their motor performance on 
the rotarod assay.  These mice were then separated into equal groups, and 
injected with 10 nmol agmatine, 10 nmol MK-801, or saline control.  15 minutes 
following injection, mice were placed on an accelerating rotarod and their latency 
to fall off of the rotarod was recorded, as presented in Figure 5.  SNI inhibited 
performance in the rotarod assay, as demonstrated by the significant decrease in 
time spent on the rotarod following injury.  Mice injected intrathecally with saline 
displayed this same impairment of rotarod performance.  However, mice injected 
with 10 nmol agmatine showed a significant increase in time spent on the 
rotarod, likely due to the analgesia provided by agmatine treatment.  Intrathecal 
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MK-801 significantly inhibited rotarod performance as compared to saline control; 
this motor impairment is characteristic of widespread NMDA inhibition.  
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Table 1: Experimental Design for Central Delivery of Agents to Modify 
Neuronal Injury-Induced Plasticity 
Day -1 Day 0 Day 1 Day 2 Day 3 
von Frey 
(vF) 
threshold 
baseline 
i.t. injection of 
10nmol study 
drug or saline 
  
Spared nerve 
injury  
vF Threshold i.t. 10 nmol 
study drug 
vF Threshold 
Day 4 Day 5 Day 6 Day 7 Days 8-30 
i.t. 10 nmol 
study drug 
vF Threshold i.t. 10 nmol 
study drug 
vF Threshold vF Threshold 
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Figure 1 
 
Figure 1: Centrally delivered agmatine attenuates the development of neuropathic 
pain behaviors following SNI.  Behavioral hypersensitivity was measured prior to and 
following SNI in saline controls (circles) compared to (A) 10 nmol agmatine (triangles), 
(B) 10 nmol MK-801 (squares) (C) 10 nmol putrescine (hexagons), or (D) 10 nmol 
ifenprodil (diamonds).  All drugs were delivered intrathecally immediately prior to and on 
days 2, 4, and 6 following spared nerve injury.  Data are expressed in grams of force 
required to elicit a behavioral response.  * represents significant difference from saline 
control, p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  ANOVA with Bonferroni post-
hoc analysis.  
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Table 2: Experimental Design for Agmatine’s Reversal of  
Hypersensitivity Induced by SNI 
Day -1 Day 0 Day 8 Day 14 Day 15 Day 16 
von Frey (vF) 
threshold 
baseline 
Spared 
nerve injury 
(SNI) 
vF 
Threshold 
vF 
Threshold 
i.t. 1 or 10 
nmol 
agmatine 
vF 
Threshold 
Day 17 Day 18 Day 19 Day 20 Day 21 Days 22-
31 
i.t. 1 or 10 
nmol 
agmatine 
vF 
Threshold 
i.t. 1 or 10 
nmol 
agmatine 
vF 
Threshold 
i.t. 1 or 10 
nmol 
agmatine 
vF 
Threshold 
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Figure 2  
 
 
Figure 2: Central delivery of agmatine reverses the expression of 
hypersensitivity following SNI.  All subjects were given SNI to induce local 
hypersensitivity and split into 3 groups of equal behavioral hypersensitivity.  15 
days following injury, subjects were given saline control (circles), 1 nmol 
agmatine (large diamonds), or 10 nmol agmatine (small diamonds), all delivered 
intrathecally on alternating days.  * represents significant difference from saline 
control.  p < 0.05, ** p < 0.01, ANOVA with Bonferroni post-hoc analysis.  
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Table 3: Experimental Design for Morphine’s Efficacy at Inhibiting  
Early and Late Stage Hypersensitivity Following SNI 
Induction 
Day -1 Day 0 Day 3 Day 4 Day 5 
von Frey (vF) 
baseline 
SNI 1 nmol 
morphine 
sulfate, 
intrathecal 
(i.t.) 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
3 nmol 
morphine 
sulfate, i.t. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
10 nmol 
morphine 
sulfate, i.t. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
Maintenance 
Day -1 Day 0 Day 14 Day 15 Day 16 
vF baseline SNI  1 nmol 
morphine 
sulfate, i.t. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
3 nmol 
morphine 
sulfate, i.t. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
10 nmol 
morphine 
sulfate, i.t. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
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Figure 3  
 
Figure 3: Centrally delivered morphine reverses neuropathic pain behaviors. 
Behavioral hypersensitivity was measured prior to and following SNI in saline controls 
(circles) compared to intrathecal morphine (squares) in induction (A-C) and maintenance 
(D-F) phases of neuropathic pain.  Data are expressed in grams of force required to elicit 
a behavioral response.  * represents significant difference from saline control, p < 0.05 ** 
p < 0.01, *** p < 0.001, **** p < 0.0001.  ANOVA with Bonferroni post-hoc analysis.  
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Table 4: Experimental Design for Agmatine’s Efficacy at Inhibiting  
Early and Late Stage Hypersensitivity Following SNI 
 
Induction 
Day -1 Day 0 Day 3 Day 4 Day 5 
von Frey (vF) 
baseline 
SNI  10 mg/kg 
agmatine, 
intravenous 
(i.v.) 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
30 mg/kg 
agmatine, i.v. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
100 mg/kg 
agmatine, i.v. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
Maintenance 
Day -1 Day 0 Day 14 Day 15 Day 16 
vF baseline SNI 10 mg/kg 
agmatine, i.v. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
30 mg/kg 
agmatine, i.v. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
100 mg/kg 
agmatine, i.v. 
 
vF testing at 
0, 30, 60, 90, 
150, 180 
minutes 
following 
injection 
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Figure 4  
 
Figure 4: Systemically delivered agmatine reverses neuropathic pain behaviors.  
Behavioral hypersensitivity was measured prior to and following SNI in saline controls (circles) 
compared to intravenous agmatine (triangles) in induction (A-C) and maintenance (D-F) phases 
of neuropathic pain.  Data are expressed in grams of force required to elicit a behavioral 
response.  * represents significant difference from saline control, p < 0.05 ** p < 0.01, *** p < 
0.001, **** p < 0.0001.  ANOVA with Bonferroni post-hoc analysis. 
 
	  	   50	  
Figure 5  
 
Figure 5: Agmatine attenuates non-reflexive pain behaviors as measured 
by rotarod performance.  All mice were assessed for their baseline motor 
coordination by rotarod performance with a cutoff time of 300 seconds, then 
given SNI to induce local hypersensitivity and assessed for their decrement in 
performance.  Students t test, **** p < 0.0001.  Following injury, subjects were 
injected with saline, 10 nmol agmatine, or 10 nmol MK-80, i.t and placed on an 
accelerating rotarod 30 minutes following injection.  Latency to fall was recorded, 
and data were analyzed by one-way ANOVA with reference to the saline control, 
* p < 0.05, ** p < 0.01. 
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Discussion 
 A key observation in these findings is that central administration of 
agmatine results in the prevention or reversal of chronic neuropathic pain 
behavior.  Most notably, Figure 1 demonstrates the reduction in chronic pain 
behaviors for days to weeks following the cessation of injection.  Agmatine was 
delivered a minimum of 12 hours prior to sensory testing, making it likely that the 
impact of agmatine is one of inhibition of neuronal remodeling instead of acute 
inhibition of evoked hypersensitivity.  The decision to administer intrathecal 
agmatine every other day and to assess sensory thresholds on the alternate 
days is in part due to agmatine’s 12 hour half-life following central delivery 
(Roberts et al. 2005).  
In addition, we sought to determine if agmatine delivery was sufficient to 
inhibit or attenuate the neuroplasticity involved in development of neuropathic 
pain.  It is important to note that agmatine attenuated the development of chronic 
neuropathic pain, in contrast to its metabolite, putrescine.  This indicates a direct 
effect of agmatine rather than a subsequent increase in putrescine following 
intravenous agmatine delivery as being responsible for the inhibition of 
maladaptive plasticity following SNI.  
 Due to NMDA inhibition’s long history as a pharmacological target, the 
side effect profile of a classic NMDA antagonist is well characterized (Olney 
1994, Neznanova et al. 2000, Lipton 2004).  Motor impairment, psychotic 
symptoms, and memory impairment are seen in both animal modeling and 
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clinically available NMDA antagonist therapeutics (Olney 1994, Lipton 2004).  In 
response to these established concerns, we have conducted a battery of side 
effect monitoring.  Presented in Figure 5, we conducted the most widely used 
assay for motor coordination, rotarod performance, and saw a significant 
increase as compared to saline controls in the time that neuropathic pain animals 
intrathecally injected with agmatine were able to walk and balance on the rotarod.  
In contrast to agmatine’s increase, intrathecally delivered MK-801 significantly 
decreased each subject’s motor coordination, as indicated by a decrease in the 
amount of time they were able to walk on the rotarod.  
In addition to time spent on the rotarod, a notable behavioral phenotype 
was observed where animals dropped their injured paw off of the rotarod and 
used only their three non-injured paws, presumably due pain-related sparing of 
the injured paw.  This observation aligns with recent publications seeking to 
characterize non-reflexive measures of pain in animal models, including voluntary 
wheel running (Grace et al. 2014) grid-climbing (Falk, Gallego-Pedersen and 
Petersen 2017), voluntary movement such as rearing or distance traveled (Cho 
et al. 2013), exploratory behavior (Zhu et al. 2012), and dynamic weight bearing 
(Laux-Biehlmann et al. 2016).  Intrathecal delivery of agmatine, shown to be 
analgesic in evaluations of mechanical hypersensitivity as measured by von Frey 
stimulation, significantly increased rather than decreased the time that 
neuropathic animals were able to sustain their position on the rotarod.  It is highly 
probable that agmatine reduced the hypersensitivity of the paw at a resting state, 
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leading to less pain-related sparing of the injured paw and an increase in the 
injured paw’s use on the rotarod, thus increasing the time spent on the rotarod as 
compared to the saline injected neuropathic controls.  In contrast, intrathecal 
delivery of MK-801 resulted in motor dysfunction characteristic of wide-spread 
NMDAR antagonism.  
 
Summary and Conclusion 
This study features the safety and efficacy of exogenous central delivery 
of agmatine as a therapeutic strategy for management of chronic neuropathic 
pain.  The pharmacology of chronically delivered agmatine reported in Figure 1 is 
comparable and improved in magnitude relative to the gold standard NMDA 
receptor antagonist MK-801 and the gold standard GluN2B-specific antagonist of 
the NMDA receptor, ifenprodil, and distinct from that of its metabolite, putrescine, 
which was inactive.  This outcome supports the proposal that agmatine acts as 
an NMDA receptor antagonist to reduce tactile hypersensitivity arising from nerve 
injury.  The pharmacology of acutely delivered systemic agmatine is comparable 
to that of morphine in that magnitude of effect, time to onset, and duration of 
action are comparable, although the potency lower.  These data indicate that 
both systemic and centrally delivered agmatine are effective for providing relief 
from tactile hypersensitivity with distinct pharmacological profiles.  These data 
contribute to the foundation for translation of safe and effective NMDA inhibition 
to a clinical setting. 
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Chapter 3: Long-Term Reversal of Chronic Pain Through  
Elevation of Spinal Agmatine 
Synopsis 
  Inhibition of pathological neuroplasticity by exogenous delivery of agmatine 
has been demonstrated in chronic neuropathic pain, as presented in Chapter 2 of 
this thesis.  The mammalian enzyme arginine decarboxylase (ADC) is thought to 
synthesize agmatine by decarboxylation of L-arginine.  Therefore, we 
hypothesized that a gene therapy overexpressing ADC may counter the effects of 
the central nervous system (CNS) disorders mentioned above.  In this chapter, I 
report that the overexpression of the ADC enzyme in tissues relevant to the pain 
pathway both prevents and reverses neuropathic pain in rodents.  
 
 
 
 
 
 
 
 
(C.P planned and conducted the experiments and behavioral analysis.  K.K. and 
R.S.P conducted experiments.  C.A.F and G.W. contributed to analysis and 
editing.)  
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Introduction 
Controlling chronic pain remains a significant scientific and clinical 
challenge and a critical public health concern (IOM 2011).  Identification of new 
pathways and approaches to counter pain arising from maladaptive 
neuroplasticity is greatly needed.  It is well established that chronic pain is 
generated and maintained due to NMDA receptor-mediated maladaptive 
neuroplasticity localized in part at the level of the spinal cord, which is the 
location of the first synapse in the sensory relay.  Pharmacological targeting of 
the NMDA receptor (Yamamoto and Yaksh 1991, Mao et al. 1992, Geng et al. 
2010, Chaplan, Malmberg and Yaksh 1997, Decosterd, Allchorne and Woolf 
2004, Qu et al. 2009, Fairbanks et al. 2000a) and associated nitric oxide 
synthase (NOS) cascade has been a broadly pursued strategy for several 
decades (Yamamoto and Shimoyama 1995, Yoon, Sung and Chung 1998, Guan 
et al. 2007, Tanabe et al. 2009, Chacur et al. 2010).  However, development of 
this strategy has been limited due to various undesirable side effects related to 
the action of NMDA receptor antagonists on CNS regions associated with motor 
and cognitive function. 
We and others have previously shown that exogenous administration of 
the NMDA receptor/NOS inhibitor decarboxylated arginine (agmatine) reduces 
manifestations of neuronal plasticity in a wide spectrum of models of CNS 
disorders (Piletz et al. 2013), including chronic pain (Courteix et al. 2007, 
Fairbanks et al. 2000b, Horvath et al. 1999).  Agmatine is distinguished from 
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most other NMDA receptor antagonists/NOS inhibitors in that it is endogenously 
produced (Satriano 2004).  Additionally, in contrast to the synthetic NMDA 
receptor antagonists, the effect of exogenous agmatine on CNS side effects 
appears to be limited or undetected in pre-clinical models of motor dysfunction 
(Fairbanks et al. 2000b, Nguyen et al. 2003).  
We hypothesized that endogenously produced agmatine can modify 
chronic pain.  Agmatine has been proposed to be generated from the enzyme 
arginine decarboxylase (ADC) (Morrissey et al. 1995),  a protein expressed in a 
variety of tissues including the CNS (Regunathan and Reis 2000).  Therefore, it 
stands to reason that genetic modification of the agmatinergic system to enhance 
endogenous production of agmatine may reduce consequences of maladaptive 
neuroplasticity.  We have previously demonstrated (Vulchanova et al. 2010) that 
intrathecal delivery of AAV5-GFP by direct lumbar puncture results in robust 
gene transfer to the dorsal root ganglia and the spinal cord, particularly at the 
lumbrosacral and cervical levels.  Therefore, we have developed an adeno-
associated viral (AAV) vector that carries the gene for ADC to determine whether 
overexpression of agmatine in tissues relevant to pain transmission can 
attenuate neuropathic pain behavior in mice.  Here we report our design and 
biological evaluation of the impact of intrathecal delivery of AAV5-hADC vectors 
that contain the synthetic human gene for agmatine.  The observations from this 
study indicate that overexpression of ADC in dorsal root ganglia and spinal cord 
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(as well as some supraspinal structures) reduces both the development and 
maintenance of chronic pain behaviors in nerve-injured rodents. 
 
Materials and Methods 
Gene Construct Development 
Human ADC cDNA was cloned into the EcoRI and Xho1 sites of plasmid 
pAAV-IRES-hrGFP (Agilent Technologies).  The resulting plasmid pAAV-ADC 
contains the ADC expression cassette (CMV promoter-ADC cDNA-IRES-GFP 
and bovine growth hormone polyadenylation signal) flanked by AAV2 inverted 
terminal repeats (Figure 2A).  This vector was packaged into AAV5 and AAV9 
virions at the University of Florida Vector Core by co-transfection of HEK293 cells 
and purified from cell lysates on an iodixanol step gradient followed by Q 
Sepharose ion exchange chromatography (Zolotukhin et al. 2002).  Vector titers 
were 8.24 or 9.77 x 1013 vector genomes/mL for AAV5-ADC-GFP (two separate 
lots were used) and 6.37 x 1013 vector genomes/mL for AAV9-ADC-GFP. 
 
Animals  
 All experiments were approved by the University of Minnesota’s Institutional 
Animal Care and Use Committee.  Experimental subjects were Institute of 
Cancer Research (ICR) male mice (21-30 grams), or Sprague Dawley rats (175-
400 grams) both from Harlan (Madison, WI).  Subjects were housed in groups of 
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4 mice or 2 rats per cage in a temperature- and humidity-controlled environment 
and maintained on a 12 hour light/dark cycle with free access to food and water. 
 
Injectates 
Agmatine, naloxone, idazoxan, putrescine, ifenprodil, and MK-801 were 
purchased from Sigma Chemical (St. Louis, MO) and diluted in 0.9% NaCl.   Anti-
agmatine guinea pig IgG or normal guinea pig IgG were developed in-house as 
previously described (Wade et al. 2009).  These were protein A-purified to the 
IgG fraction, concentration-matched, and diluted in 0.9% NaCl at 150 ng/5 
microliter injection.  All viral vectors used in these experiments were packaged 
and/or purchased from the Vector Core of the University of Florida, Gainesville, 
Florida.  
 
Intrathecal Injections  
All viral vectors, drugs, or IgGs were administered intrathecally (i.t.) by direct 
lumbar puncture in conscious rodents as described for mice (Hylden and Wilcox 
1980) and rats (Mestre et al. 1994).  Briefly, the subjects were gently gripped by 
the iliac crest and a 30-gauge, 0.5 inch needle (mice) or 27 gauge 1.4 inch 
needle (rats) connected to a 50-µL Luer-hub Hamilton syringe was used to 
deliver 5 µL of injectate in the intrathecal space.  In the case of viral vector 
injection, a modified needle, catheter, syringe apparatus was used to inject 10 
microliters of injectate in order to conserve product.  AAV5-GFP or AAV9-GFP 
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stocks (purchased from University of Florida, Vector Core, Gainesville, Florida) 
were diluted to titer match the corresponding AAV-hADC titers prior to injection.  
In the case of the AAV5 vectors, the hyperosmotic agent mannitol (25%, 200 
microliters, tail vein) was delivered as an intravenous pre-treatment to enhance 
distribution of the AAV5 vectors to the CNS following intrathecal delivery 
(Vulchanova et al. 2010).  By contrast, mannitol pre-treatment does not enhance 
CNS distribution of AAV9 serotype after intrathecal delivery (Schuster et al. 2014) 
and so it was not used in the experiments using the AAV9 serotype.  
 
RT-PCR   
Total RNA was extracted from tissue or cell lines using RNAzol RT 
(Molecular Research Center, Cincinnati, OH) according to manufacturer’s 
suggestions.  Approximately 1.3 micrograms of this RNA was reverse-
transcribed.  Briefly, the RNA was added to a reverse transcription (RT) master 
mix (final concentrations: 2.5 U Multiscribe murine leukemia virus reverse 
transcriptase, 2.5 mM random hexamers, 200 µM of each dNTP, 5 U RNase 
inhibitor, 5.0 mM dithiothreitol, 1.75 mM MgCl2, 30 mM tris-HCl and 20 mM KCl; 
pH 8.3) in a volume of 40 µl.  cDNA synthesis was performed in a thermal cycler 
(BioRad Mini) with the following program: 25°C for 5 minutes (primer annealing), 
42°C for one hour (primer extension) and 65°C for 5 minutes (inactivation of the 
reverse transcriptase).  4.5 µl of RT reaction product was added to 10 µl 
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Lightcycler 480 SYBR green I Master (Roche, Indianapolis, IN) and 15 µM of 
each forward and reverse primer in a total of 20 µl per reaction.  The sequences 
of the primers used are shown in Table 2.  PCR amplification was performed in 
thermal cycler (Lightcycler 480 II, Roche) using the following program: 1 cycle of 
95˚C for 5 minutes (DNA polymerase activation) followed by 50 cycles of 95˚C for 
10 seconds (DNA denaturation), 57˚C for 10 seconds (primer annealing) and 
72˚C for 10 seconds (primer extension).  PCR amplification was followed by built-
in melting temperature and cooling programs.  Ten µl of PCR product was 
fractionated through a 1.5% agarose gel, visualized by ethidium bromide staining 
and imaged using a digital workstation (BioRad). 
 
Spared Nerve Injury  
Spared nerve injury (SNI) was induced in rodents according to the method 
described by Decosterd and Woolf (Decosterd, Allchorne and Woolf 2002).  The 
left sciatic nerve and its three terminal branches were exposed under isoflurane 
anesthesia.  The common peroneal and tibial nerves were ligated with a 5.0 silk 
suture and sectioned distal to the ligation, removing 2-4 mm of the distal nerve 
stump.   
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Mechanical sensory assessment  
All subjects were assessed for responsiveness to mechanical stimulation 
using an electronic von Frey anesthesiometer (IITC Life Sciences, Woodland 
Hills, USA).  Mice were placed in glass enclosures on an elevated mesh screen 
and permitted to acclimate for 15-30 minutes prior to stimulation.  The electronic 
von Frey probe was gently applied to each hindpaw until a brisk withdrawal 
response terminated application of pressure (within seconds).  The paw 
withdrawal thresholds were recorded.  All measurements were taken by a single 
experimenter blinded to genetic and/or pharmacological treatment.  
  
Analysis of AAV Tissue 
Tissue extract was diluted 1:20 into 200 mM borate buffer (pH 9.3) to 
neutralize the TCA and transferred 10 µL to a fresh microfuge tube along with 5 
µL Internal Standard (1 µM, piperazine-1-carboxamidine hemisulfate, Oakwood 
Products).  Agmatine spike was 10 µL of 1 µM agmatine sulfate.  Borate buffer 
was added to bring total volume to 55 µL.  Each reaction then received 5 µL of 
NBD-F solution (100 mM, acetonitrile, Molecular Probes), and was quickly mixed 
and centrifuged, and incubated for 30 min at 60 oC.  After incubation, all reactions 
were centrifuged 20 min, 16,000 × g, 4 oC to clarify. 
 Derivatized samples were injected for 5 seconds at 0.5 psi into a fused 
silica capillary (50 µm i.d., 39 cm) in a commercial capillary electrophoresis 
system (MDQ, Beckman-Coulter) with LIF detection (488 nm excitation). 
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Samples were run at 15 kV for 30 min with 34 mM (2-hydroxypropyl)-β-
cyclodextrin (Sigma-Aldrich) in 200 mM borate buffer (pH 9.3) running buffer at 
capillary temperature of either 25 oC or 50 oC .  Before each run, the capillary 
was rinsed with 1 M NaOH, diH2O, and running buffer.  Data were exported to 
Cutter 7.0 for peak integration (Shackman, Watson and Kennedy 2004) and 
normalization by total protein. 
 
 Motor Coordination 
Motor coordination was assessed via an accelerating rotarod (Ugo Basile, 
Carese, Italy).  After a training session, mice were given the opportunity to walk 
on an acceleration (4-40 rpm) rotarod for a maximum of 300 seconds.  We 
recorded and compared the latency to fall off of the rotarod between treatment 
groups.  
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RESULTS  
Expression of Human Arginine Decarboxylase in the Sensory System 
We hypothesized that overexpression of the synthetic enzyme for 
agmatine, arginine decarboxylase (ADC, Figure 1) (Morrissey et al. 1995), in the 
sensory neurons of the dorsal root ganglia and spinal cord would reduce 
neuropathic pain.  To test this hypothesis, we generated an AAV5 vector 
expressing human ADC (hADC) under transcriptional regulation by a CMV 
promoter (Figure 2).  Using human ADC rather than rodent ADC for gene transfer 
enabled us to independently distinguish between the two ADC forms in 
transduced tissue and, therefore, assess the efficacy of gene transfer to the 
spinal cord and dorsal root ganglia.  In Figure 2B, we show that species-specific 
primers can detect native human hADC present in human embryonic kidney 
(HEK) 293 cells, but do not detect mouse ADC in spinal cord tissue extracted 
from mice treated with control AAV5-GFP vector.  These primers also fail to 
detect mouse ADC in mouse fibroblast 3T3 cells, but detect hADC in 3T3 cells 
treated with AAV5-hADC vector.  These experiments confirm the specificity of the 
primers for human ADC.  In two independent experiments, 8.7 x 10(11) total vector 
genomes (10 microliters) of AAV5-hADC were injected intrathecally by direct 
lumbar puncture in nerve-injured mice.  We evaluated the expression of hADC at 
lumbar and cervical levels both in spinal cord and DRG.  RT-PCR analysis 
revealed transgene expression along the spinal cord and further rostrally into the 
brain (Figure 2C).   
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The tissue distribution is summarized in Table 1.   
 
Intrathecal Pretreatment with AAV-hADC Reduces of Neuropathic Pain 
Behaviors in Mouse and Rat 
Six weeks following intrathecal injection of either AAV-hADC, AAV-GFP 
(control for vector and GFP effects), and saline (control for injection effects), the 
sensory responses to mechanical stimuli were evaluated prior to and following 
unilateral spared nerve injury in mouse (Figure 3A) and rat (Figure 3B).  AAV-
hADC treatment resulted in an increasing significant elevation of paw withdrawal 
thresholds in injured subjects over the testing period whereas treatment with 
AAV-GFP or saline had no effect on paw withdrawal thresholds.  These data 
demonstrate that the additional expression of human arginine decarboxylase in 
DRG, spinal cord or choroid plexus results in a reduction in neuropathic pain 
behaviors.  
 
Anti-Agmatine IgG Reverses AAV5-hADC Inhibition of Neuropathic Pain  
To further determine whether the reduced neuropathic pain responses in 
AAV5-hADC treated mice were attributable to an effect of the agmatine molecule, 
we used an alternative indirect approach: immunoneutralization.  We assessed 
the impact of intrathecal delivery of an immunoneutralizing antibody (IgG-Ag) 
(Wade et al. 2009) on the antihyperalgesic effect observed in AAV5-hADC-
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treated mice.  In this experiment, a second larger cohort of mice  (n = 24) were 
treated with AAV5-ADC in order that there would be sufficient numbers of 
transduced subjects to test with anti-agmatine IgG and to compare with controls 
injected with normal IgG.  An additional set of subjects included a smaller cohort 
(n = 8) of mice treated with AAV5-GFP to represent the expected level of nerve 
injury-induced hyperalgesia.  On day nine after SNI surgery, the AAV5-hADC 
treated subjects were divided into two separate groups with equivalent levels of 
hypersensitivity.  Twelve mice received anti-agmatine IgG (150 ng/5 µL) and 
twelve mice received normal IgG (150 ng/5 µL).  Those injected with anti-
agmatine IgG, but not normal IgG, showed significantly reduced von Frey 
thresholds at 30 minutes post-injection (Figure 4), a result repeated a week later 
with additional time points included: 2 and 4 hours post-injection.  To exclude the 
possibility that other endogenous analgesic substances may contribute to the 
observed effect, the opioid receptor antagonist naloxone and the alpha-2 
adrenergic antagonist idazoxan were tested for reversal of the effects of AAV5-
hADC at doses confirmed to be effective against their respective agonists 
(morphine and clonidine, data not shown).  Neither antagonist had an effect on 
the withdrawal thresholds of AAV5-hADC-treated mice, ruling out potential 
contribution of opioid neuropeptides or norepinephrine.  The reversal of the 
effects of AAV5-hADC by treatment with the anti-agmatine IgG supports the 
proposal that the overexpression of hADC generates endogenous agmatine, 
leading to the observed anti-hyperalgesia in AAV5-hADC-treated subjects. 
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Treatment of Nerve-Injured Mice with AAV9-hADC Reduces Mechanical 
Hypersensitivity  
Therefore, we evaluated whether hADC gene transfer following nerve 
injury could similarly alleviate previously established hypersensitivity.  Nerve-
injured mice with mechanical hypersensitivity were injected with either AAV9-
hADC or saline on day 8 post-surgery.  As early as day 24 post-injection (day 32 
post-injury), the AAV9-hADC-treated subjects showed significantly reduced 
hyperalgesia compared to saline-injected controls (Figure 5).  These data 
indicate that gene transfer of hADC following an established chronic pain state 
significantly reduced hypersensitivity within 3 weeks of injection, an effect that 
persisted during the subsequent five weeks of testing.  The AAV9-hADC-treated 
subjects were then divided into two groups with equivalent sensory thresholds 
and the observed anti-hyperalgesia was assessed for agmatine dependence 
using the immunoneutralization approach described previously.  Those injected 
with anti-agmatine IgG, but not normal IgG, showed significantly reduced von 
Frey thresholds at 4 hours post-injection, suggesting that agmatine contributes to 
the effect of AAV9-hADC.  
 
Reversal of Long-Established Neuropathic Hypersensitivity by Agmatine 
Production via AAV-hADC 
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 Since nerve injury and the subsequent development of chronic pain are 
often not predictable and takes significant time to establish, patients most often 
present  to the clinic following long establishment of their chronic pain.  
Therefore, in order to more closely model that time frame pre-clinically, we next 
sought to evaluate whether hADC gene transfer following nerve injury could 
alleviate long-established hypersensitivity.  Mice were evaluated for their baseline 
von Frey behavioral thresholds, then hypersensitivity was induced with SNI 
surgery.  Mice were evaluated again for von Frey thresholds 256 days following 
nerve injury, split into groups of equal responding, and injected intrathecally with 
saline or AAV5-hADC on day 266 following injury (Figure 6).  The AAV5-hADC-
treated subjects showed significantly increased von Frey thresholds compared to 
their saline counterparts for the duration of the experiment, up to 95 days post-
injection and a year post-injury, at which time both cohorts were sacrificed and 
tissue was collected for bioanalytical analysis, which confirmed both presence of 
ADC mRNA in sensory tissues and elevated agmatine in lumbar spinal cord 
(Fairbanks, unpublished observations).  This experiment is important because it 
demonstrates an ability to alleviate chronic pain of long duration, a form of 
chronic pain that is known to be particularly difficult to treat and manage.  
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AAV5-hADC Partially Restores Impaired Motor Performance in Nerve-
Injured Mice 
 In Chapter 2, I reported that intrathecal delivery of agmatine improved 
rotarod performance of nerve-injured subjects, likely due to a reduction of 
hypersensitivity in the injured paw.  I sought to perform a direct parallel of that 
experiment using AAV9-hADC gene transfer rather than exogenous agmatine. 
Four cohorts were run in parallel: naïve control, sham-injured control (a muscular 
incision was made but the nerves remained undisturbed), nerve-injured subjects 
that received intrathecal saline, and nerve-injured subjects that received 
intrathecal AAV9-hADC to increase spinal agmatine.  Mice were placed on an 
accelerating rotarod and their latency to fall off was recorded (Figure 7).  There 
was no difference in performance between naive subjects and subjects that 
received sham surgery.  However, there was a significant decrement in 
performance between subjects that received sham surgery and subjects that 
received nerve injury with intrathecal saline treatment, indicating that the 
hypersensitivity following nerve injury is responsible for this large decrement in 
performance.  Subjects that received intrathecal AAV9-hADC following nerve 
injury displayed significant improvement over their saline-injected, nerve-injured 
controls, likely due to agmatine’s analgesic effect in the hypersensitive paw.  
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Figure 1 
 
 
 
Figure 1: Agmatine synthesis and degradation.  Agmatine is synthesized by 
arginine decarboxylase (ADC) from L-arginine.  Agmatine is metabolized by 
agmatinase (AGM) into putrescine.  
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Figure 2 
 
Figure 2: Gene construct for AAV5-hADC and AAV9-hADC viral vectors.  
A) TR - terminal repeats, CMV – cytomegalovirus, ADC – arginine 
decarboxylase, IRES – internal ribosome entry site, GFP – green fluorescent 
protein, pA – poly adenylation.  B) Specificity of human ADC as measured in 
HEK 293 cells, mouse spinal cord injected with AAV5-ADC, mouse 3T3 cells, 
and mouse 3T3 cells treated with AAV5-hADC.  C) Expression of hADC in DRG 
following AAV 
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Figure 3 
 
Figure 3: AAV5-hADC pre-treatment inhibits hypersensitivity following 
neuropathic injury in mice and rats.  A minimum of 4 weeks prior to spared nerve 
injury, mice (A) or rats (B) were intrathecally injected with AAV5-hADC (diamonds), 
AAV5-GFP (inverted triangles) or saline control (circles).  von Frey mechanical testing 
was performed on injured (ipsilateral) and non-injured (contralateral) paws both prior to 
and following injury, reported here in grams of force.  * represents significant difference 
from saline control.  p < 0.05, ANOVA with Bonferroni post-hoc analysis. 
	   76	  
Figure 4 
 
Figure 4: Immunoneutralization of agmatine re-establishes hypersensitivity 
following AAV-ADC treatment in neuropathic pain.  Mice were injected with either 
AAV5-GFP (control, circles) or AAV9-hADC 6 weeks prior to SNI.  Following 
establishment of injury, AAV9-hADC mice were separated into two groups of equal von 
Frey thresholds (upright triangles and inverted triangles).  On days 9 and 16, these two 
groups were injected with either normal IgG (upright triangles) or anti-agmatine IgG 
(inverted triangles) and von Frey thresholds were assessed.  On day 23, this paradigm 
was repeated with naloxone (inverted triangles) or saline (upright triangles).  On day 30, 
this paradigm was repeated with idazoxan (inverted triangles) or saline (upright 
triangles).  * represents significant difference from saline control.  p < 0.05, ANOVA with 
Bonferroni post-hoc analysis. 
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Figure 5 
 
Figure 5: Immunoneutralization of agmatine re-establishes hypersensitivity 
following AAV-ADC post-treatment of neuropathic pain.  One week following spared 
nerve injury, mice were separated into two groups of equal von Frey mechanical 
thresholds and intrathecally injected with saline (circles) or AAV9-hADC.  On day 54 
following injury, mice that received AAV9-hADC were separated into two groups of equal 
responding; the first group received anti-agmatine IgG (inverted triangles) and the 
second group received normal IgG (upright triangles). von Frey thresholds were taken 1 
and 2 hours following injection.  * represents significant difference from saline control.  p 
< 0.05, ANOVA with Bonferroni post-hoc analysis.  # represents significant difference 
from normal IgG, p < 0.05, Student’s t-test.  
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Figure 6 
	  
 
Figure 6: Reversal of long-established neuropathic hypersensitivity by 
agmatine production via AAV-hADC.  All mice were assessed for their 
baseline mechanical hypersensitivity via von Frey probe and then given spared 
nerve injury to induce local hypersensitivity.  Mice received i.t. saline (circles) or 
AAV5-hADC (diamonds) 266 days following injury and hypersensitivity was 
measured up to 95 days following injection. Following completion of behavioral 
analysis, spinal cord tissue was collected and analyzed for agmatine content.   
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Figure 7 
 
 
Figure 7: AAV5-hADC partially restores impaired motor performance in nerve-injured 
mice.  Four groups of mice were run in parallel: Non-injured controls (naïve), sham surgery 
controls lacking neuropathic injury (sham), mice that received saline treatment prior to 
neuropathic injury (SNI Saline), and mice that received AAV9-hADC prior to neuropathic 
injury (SNI AAV9-hADC).  All mice were assessed for their von Frey thresholds (A) and 
motor coordination (B) by rotarod performance with a cutoff time of 300 seconds.  Latency to 
fall was recorded, and data were analyzed by one-way ANOVA with reference to the injured 
saline control, p < 0.05 *** p < 0.001. 
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Table 1: mRNA Expression in Tissue Following AAV5-hADC i.t. Injection 
Tissue 
Region 
  
Day 
Post 
SNI 
Lumbar 
Spinal 
Cord 
Cervical 
Spinal 
Cord 
Lumbar 
DRG 
  
Cervical 
DRG 
Choroid 
Plexus  
(4th 
Ventricle) 
hADC 
expression 
in any 
tissue 
Day 11  
(n=19) 
* 61% 
(11/18) 
37% 
(7/19) 
42% 
(8/19) 
* 74%  
(14/19) 
Day 51  
(n=23) 
74% 
(17/23) 
95% 
(21/22) 
33% 
(7/21) 
61% 
(13/21) 
57% 
(13/23) 
96%  
(22/23) 
Note: the denominators do not always reflect samples from the entire cohort.  In 
some cases, the samples were not collected or collectable.  In some cases, the 
RNAzol extraction procedure yielded less than 1.3 µg mRNA.  
*Tissues not analyzed by PCR  
 
hADC mRNA expression in spinal cord and dorsal root ganglia (DRG) at 53 and 
92 days following the initial intrathecal injection of AAV5-hADC.  These days 
corresponded respectively to day 11 and Day 51 post-SNI surgery.  Spinal cord 
(lumbar, cervical), DRG (lumbar, cervical) and choroid plexus (4th ventricle) 
tissues were microdissected from AAV5-hADC injected mice.  The tissues were 
assayed by RT-PCR for the presence of hADC mRNA as determined by agarose 
gel electrophoresis.  
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Table 2.  Sequences of Primers Used in RT-PCR Experiments 
Name of Primer Sequence 
hADC forward set 2 GCCTTGGACCTGTACTTCCC 
hADC reverse set 2 CTGGTCCGTGGATGGTTTCT 
b-actin forward qPCR TCATGTTTGAGACCTTCAACAC 
b-actin reverse qPCR ATGTCACGCACGATTTCCC 
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Discussion 
We and others have previously demonstrated that intrathecally or 
systemically delivered agmatine reduces multiple manifestations of 
neuroadaptive pathological plasticity (Piletz et al. 2013), including neuropathic 
pain as was discussed in Chapter 2 (Courteix et al. 2007, Onal et al. 2003, 
Karadag et al. 2003, Fairbanks et al. 2000b).  The current study illustrated that 
the pain pathway-related regions of the dorsal root ganglia and spinal cord were 
transduced with the human form of the enzyme arginine decarboxylase following 
intrathecal delivery of AAV5 of AAV9 vector carrying the gene for the enzyme.   
This enzyme is known as the synthetic enzyme of the arginine metabolite, 
agmatine (Morrissey et al. 1995).  Following gene transfer of the human form of 
arginine decarboxylase, the neuropathic pain behaviors were significantly 
reduced in magnitude and remained reduced for several months post-injection.  
A logical explanation is that elevated production of endogenous agmatine could 
account for such a behavioral response, analogous to what is observed with 
exogenous delivery of agmatine seen in Chapter 2.  A significant finding of these 
studies is the ability of this gene transfer to reduce long-established 
hypersensitivity (Figure 6), up to 266 days post-injury.  This finding greatly 
strengthens the viability of translation of agmatine and ADC gene transfer for use 
in a clinical setting.   
In order to test the validity of the above explanation that endogenous 
	   83	  
agmatine arising from the AAV-hADC treatments was responsible for the 
antihyperalgesic effects, we pursued an indirect approach.  We applied an 
immunoneutralization strategy using scavenging antisera to determine whether 
endogenous agmatine accounted for the anti-hyperalgesic effects of the AAV-
hADC treatment.  This method has been widely used to assess the effects of 
endogenous analgesic substances (Vanderah et al. 1994, Tseng et al. 2000, 
Ohsawa et al. 2001) and recently endogenous pro-nociceptive substances 
(Fairbanks et al. 2014).  We previously demonstrated that a structure-specific 
anti-agmatine (AG) immunogammaglobulin (IgG) reversed the pharmacological 
effects of exogenously applied intrathecal agmatine (Wade et al. 2009).  We 
therefore reasoned that intrathecal administration of the anti-agmatine (AG) IgG 
antibody should similarly reverse the pharmacological effects of endogenous 
agmatine presumed to be produced by the overexpression of hADC.  In fact, 
when immunoneutralizing antibodies selective for agmatine were delivered 
intrathecally, the magnitude of the reduction in neuropathic pain behavior was 
significantly reduced.  The selectivity of this effect for agmatine is indirectly 
supported by the observations that such a reduction was not observed with 
normal IgG, the opioid receptor antagonist naloxone, or the alpha2 adrenergic 
antagonist, idazoxan.  Specifically, the lack of effect of the normal IgG indicates 
that anti-Ag IgG reversal of the effect of AAV-hADC overexpression on 
neuropathic pain is not a random effect of the IgG.  Further, the observation that 
intrathecal naloxone and idazoxan both fail to have an effect indicates that the 
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effect of AAV-hADC overexpression on neuropathic pain is not due to random 
compensatory responses of the opioidergic or noradrenergic endogenous 
analgesic systems.  Therefore, these observations support the proposal that 
elevated endogenous agmatine contributes to the anti-hyperalgesic effect of the 
AAV5-ADC treatment.   
In addition to von Frey mechanical testing, we also probed for a non-
evoked measurement of hypersensitivity following nerve injury.  To this end, we 
assessed rotarod performance in naïve, sham-injured, nerve-injured with saline 
control, and nerve-injured with AAV9-hADC treatment (Figure 7).  Similar to my 
finding in Chapter 2, mice that received AAV9-hADC therapy were able to walk 
on the accelerating rotarod for a significantly longer amount of time than their 
saline-treated, injured controls.  This outcome likely results from a decrease in 
sensitivity upon use of the paw to continue walking on the accelerating rotarod. 
Taken together, these results indicated that gene therapy, applied to 
enhance the agmatinergic system, may be feasible for management of chronic 
pain.  When considering that pharmacologically delivered agmatine has other 
therapeutic effects, it seems likely that other forms of maladaptive neuroplasticity 
may be suitable candidates for AAV-ADC treatment.  However, to date, the 
agmatinergic system has been minimally investigated; expanded scholarship is 
greatly needed to understand the relationship of this system to that of 
pathological and physiological neuroplasticity as well as its general role in the 
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CNS in order to fully understand and assess its potential for therapeutic 
applications.  
 
Summary and Conclusion 
We have demonstrated that a single intrathecal injection (either before or 
after the establishment of nerve injury) of AAV vector carrying the gene for 
arginine decarboxylase results in persistent reduction of chronic pain, in an 
apparently agmatine-dependent manner even for long-established chronic pain. 
An emerging literature suggests that such a gene therapy approach is likely to be 
clinically translatable with a large gene load capacity and long-term expression 
(Beutler and Reinhardt 2009) which may be valuable for certain chronic pain 
conditions for which long term pharmacological treatments have challenges. 
Intrathecal delivery of AAV-ADC will be assessed in further studies to determine 
the effectiveness in other pain conditions. 
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Chapter 4: Agmatine Requires the GluN2B Subunit to Inhibit NMDA 
Receptor-Mediated Neurobehavioral Plasticity 
 
Synopsis 
 The data presented in Chapters 2 and 3 strongly support agmatine’s 
action as an antagonist of the NMDA receptor.  Based on our preliminary data, 
we hypothesized that a subunit of the NMDA receptor, specifically GluN2B, is 
required for agmatine’s effect at this receptor.  In order to confirm the hypothesis 
that agmatine requires the 2B subunit of the N-methyl-D-aspartate receptor 
(NMDAR) to inhibit neuronal signaling, it is necessary to test this using a genetic 
knock down approach.  The study presented in this chapter utilized a GluN2B-
floxed mouse line developed at Vanderbilt University to test whether GluN2B-
containing NMDA receptors are required for agmatine’s reduction of neuropathic 
pain and opioid analgesic tolerance.  
 
 
 
 
 
 
(C.P planned and conducted the experiments and behavioral analysis.  K.K. 
conducted experiments.  H.V conducted molecular analysis.  C.A.F and G.W. 
contributed to analysis and editing.) 
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Introduction 
 Agmatine, the small molecule synthesized from L-arginine via arginine 
decarboxylase (ADC), has long been thought to act as an endogenous 
neurotransmitter/neuromodulator.  Agmatine, ADC, and agmatine’s degradative 
enzyme agmatinase are all expressed in mammalian tissues (Li et al. 1994, 
Raasch et al. 1995).  Agmatine was first described as an endogenous agonist of 
imidazoline receptors (Li et al. 1994).   A study examining glutamate-induced 
neurotoxicity conducted in HEK-293 cells concluded that agmatine likely interacts 
with a site located within the channel pore of the NMDA receptors expressing 
NR1-1a and NR2C subunits (Olmos et al. 1999).  Further, agmatine has been 
directly shown to inhibit NMDA receptor channels in whole-cell patch clamp 
studies, where it produced a concentration- and voltage-dependent block of 
NMDA receptor currents (Yang and Reis 1999).  Despite the foundation of these 
studies, no functional in vivo assay of agmatine efficacy has previously been 
conducted to probe the necessary composition of the NMDA receptor for the 
inhibitory effects of agmatine in models of neuropathic pain or opioid tolerance.  
 
NMDA Receptor Characteristics Following Neuropathic Pain  
 The NMDA receptor is composed of four subunits (Furukawa et al. 2005), 
typically composed of two GluN1 and two GluN2 subunits (Paoletti, Bellone and 
Zhou 2013).  Of the GluN2 subunits, four subtypes exist (A-D), with each having 
differential expression and functional properties across the central nervous 
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system and throughout development (Traynelis et al. 2010), and each encoded 
by a separate gene (Kutsuwada et al. 1992).  The subunit composition 
determines the pharmacological and physiological characteristics of each NMDA 
receptor (Monyer et al. 1992); NR1/NR2A receptors display a faster inactivation 
rate than NR1/NR2B receptors (Vicini et al. 1998).  
NMDA receptor activity is altered in several ways following peripheral 
nerve injury.  The NR1 subunit experiences a significantly increased 
phosphorylation level in dorsal spinal cord and gracile nucleus ipsilateral to the 
site of injury as compared to the contralateral side (Ultenius et al. 2006, Gao et 
al. 2005).  Wind-up (the ramping up of the number of spikes evoked by repeated 
C-fiber stimuli arising from the periphery (Herrero, Laird and López-García 2000)) 
following peripheral injury can be inhibited by NMDA antagonists such as 
ketamine, MK-801 and the GluN2B-selective antagonists memantine, RO-25 
6981, and ifenprodil (Suzuki, Matthews and Dickenson 2001, Qu et al. 2009). 
Analysis of the GluN2B-selective NMDA antagonists indicates GluN2B-containing 
NMDA receptors are critical to the development of neuropathic pain at early 
stages following injury, and for the development of long-lasting enhanced spinal 
excitability.  
Further evidence supporting GluN2B’s involvement in the spinal plasticity 
and central sensitization of pain lies in the tyrosine phosphorylation of this 2B 
subunit and its increase in multiple pain states (Luo et al. 2014, Liang et al. 2017, 
Bu et al. 2015, Guo et al. 2002).  NMDA receptor responses to agonists are 
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enhanced following phosphorylation (Zhou, Chen and Pan 2011).  Following 
injection of complete Freund’s adjuvant, a prolonged increase in tyrosine 
phosphorylation of GluN2B but not GLuN2A is correlated to the temporal 
expression of hyperalgesia and inflammation (Guo et al. 2002).  Injection of 
saline results in only a transient increase in tyrosine phosphorylation of NR2B, 
indicating that the phosphorylation of GluN2B is maintained by primary afferent 
input from the site of injury.  Taken in total, these data indicate that targeting the 
GluN2B subunit of the NMDA receptor following neuropathic pain is a viable 
strategy to reduce neuropathic pain.  
 
Probing the GluN2B Subunit in vivo 
Pharmacologically, compounds such as ifenprodil (Gallagher et al. 1996), 
RO 25-6981 (Lynch et al. 2001), and polyamines and protons (Gallagher et al. 
1997) demonstrate selectivity for the 2B over the 2A subunits of the NMDA 
receptor.  Probing the physiological function and relevance of the 2B subunit of 
the NMDA receptor has historically been difficult to resolve.  One early study 
utilizing mutant mice deficient in this subunit concluded that GluN2B was 
essential for synaptic plasticity and neuronal pattern formation; these mice lacked 
a suckling response and died shortly after birth unless hand-fed (Kutsuwada et 
al. 1996), likely due to NMDA-mediated developmental regulation (Hestrin 1992). 
The hippocampus of these mutant mice did not respond to a standard long-term 
depression (LTD) protocol and lacked synaptic NMDA responses in the 
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trigeminal nucleus.  These results indicate that the 2B subunit is required for 
development, synaptic plasticity and neuronal pattern formation such as in the 
formation of memory.  
Advances in gene editing technology led to the development of GluN2B-
floxed mice (Brigman et al. 2010).  These mice were initially crossed with 
transgenic mice expressing CAMKII-driven Cre recombinase, which enabled the 
production of mice with reduced GluN2B expression in neurons of the cortex and 
CA1 region of the hippocampus.  Further studies utilizing these mice have 
indicated their viability for use in a site-specific knock down of GluN2B (Radke et 
al. 2017, Wills et al. 2012).  In order to knock down GluN2B, we used an 
intrathecal injection of AAV9 virus carrying the gene for Cre-recombinase driven 
by a CMV promoter.  This approach enabled us to selectively knock down 
GluN2B largely restricted to spinal cord tissue.  
 
Agmatine Modulates Opioid Analgesic Tolerance 
 In addition to agmatine’s direct modulation of tactile hypersensitivity 
following injury, agmatine has also been shown to modulate the efficacy of opioid 
analgesia (Su, Li and Qin 2003) and prevent the development of  opioid 
analgesic tolerance (Kolesnikov, Jain and Pasternak 1996, Fairbanks and Wilcox 
1997) through indirect interaction with opioid receptors.  This action occurs 
through their inhibition of NMDA receptors as previously discussed (Elliott et al. 
1995), but also through agmatine’s action as a competitive NOS inhibitor (Galea 
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et al. 1996).  These observations support the development of agmatine as an 
adjunct therapeutic to be delivered alongside opioids to increase the therapeutic 
potential of opioids while reducing undesirable side effects of opioids including 
tolerance and dependence.  Previous work has shown that agmatine given alone 
in doses of 0.1 or 10 mg/kg had no significant effect in a mouse tail flick assay 
(Kolesnikov et al. 1996).  However, delivery of agmatine alongside morphine 
shifts morphine’s ED50 2-9 fold, depending on the route of morphine’s 
administration (intracerebroventricularly (i.c.v.) and intrathecally (i.t.), 
respectively).  As an extension of these results, daily i.c.v. injections of 10 nmol 
agmatine alone does not potentiate acute morphine analgesic potency compared 
to saline controls (Kitto and Fairbanks 2006).  These results support the 
argument that agmatine’s attenuation of morphine tolerance is not due to acute 
potentiation of morphine analgesia.  It then becomes necessary to probe 
agmatine’s impact on the development of morphine tolerance in mice, as well as 
the necessity of the 2B subunit of the NMDA receptor in lumbar spinal cord on 
this impact.  
 
Materials & Methods 
Animals 
The GluN2B-floxed allele mouse was generated by the Gene-Targeted 
Mouse Core of the INIA-stress consortium, as previously described (Brigman et 
al. 2010).  This Integrative Neuroscience Initiative on Alcoholism examines the 
	   96	  
link between stress and alcohol.  The consortium is supported by the National 
Institute on Alcohol Abuse and Alcoholism.  The Gene-Targeted Mouse Core is 
supported by NIH grant U01 AA013514 to Eric Delpire. 
 
Intrathecal injections 
All drugs were dissolved in sterile saline and delivered in 5-μl volumes via 
intrathecal injection in conscious mice (Hylden and Wilcox 1980).   Briefly, the 
mice were held by the iliac crest and a 30-gauge, 0.5 inch needle attached to a 
50-µL Luer-hub Hamilton syringe delivered 5 µL of injectate into the intrathecal 
space of the mice.  
 
Spared Nerve Injury 
Tactile hypersensitivity was induced using the spared nerve injury model 
described by Decosterd and Woolf (Decosterd, Allchorne and Woolf 2002).  
Subjects are placed under isoflurane anesthesia and the left sciatic nerve is 
exposed, along with its three terminal branches.  The common peroneal and tibial 
nerves were ligated with 5.0 silk suture.  The nerves were sectioned 2 mm distal 
to the ligation site.  The sural nerve remained uninjured.   
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Tactile Hypersensitivity  
Mice were placed on a wire mesh grid under a glass enclosure and 
allowed to acclimate for 30 minutes prior to testing.  Hypersensitivity was tested 
by using an electronic von Frey device (Life Sciences, IITC).  The left and right 
hindpaws were stimulated by the tip of the stimulator with enough force to cause 
the mouse to withdraw its paw.  The amount of force required for withdrawal was 
recorded in grams.  Baseline responses before SNI were collected, and the 
%MPE was calculated by the following formula: (Experimental Value-
Control)/(Cutoff-Control) X 100.  For the purpose of these experiments, the 
following measurements were used: (Post-Drug Threshold – Pre-Drug 
Threshold)/(Pre-Surgery Baseline Threshold – Pre-Drug Threshold) X 100.  
 
Induction of Morphine Analgesic Tolerance  
 Morphine tolerance was induced in mice by repeated administration of 
intrathecal morphine over the course of four days.  Mice were assessed for their 
baseline nociceptive responsiveness on Day 1, followed by an intrathecal 
injection of 10 nmol morphine (control) or 10 nmol morphine + 10 nmol agmatine 
(experimental).  On days 2, 3 and 4, mice received twice daily intrathecal 
injections and a tail flick assay following the second injection.  All injections were 
delivered in a volume of 5 microliters.  
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Warm Water Tail Immersion  
 A warm water (52.5 °C) immersion tail-flick assay was used to assess 
nociceptive responsiveness (PA, CJ and JG 1963).  Baseline measurements of 
tail-flick latencies were collected on every subject and each subject’s baseline 
was used as its own control.  The maximum possible effect (%MPE) was 
calculated as follows: %MPE = (postdrug latency – predrug latency) / (cutoff – 
predrug latency) x 100%.  A maximum score of 100% was assigned to animals 
that did not show responsiveness before the 12-second cutoff to avoid tissue 
damage.  
 
Generation of GluN2B-Deficient Mice  
Generation of the GluN2B mouse was initiated by Dr. E. Delpire 
(Vanderbilt University), as previously described (Brigman et al. 2010).  The 
GluN2B mutant mouse was generated by the Gene-Targeted Mouse Core of the 
INIA-stress consortium.  This Integrative Neuroscience Initiative on Alcoholism 
examines the link between stress and alcohol.  The consortium is supported by 
the National Institute on Alcohol Abuse and Alcoholism.  The Gene-Targeted 
Mouse Core is supported by NIH grant U01 AA013514 (to E.D.).  A breeding 
colony of homogenous GluN2B-floxed mice was established.  At time of weaning 
(p21), all subjects received either an intrathecal injection of 5 microliters of 0.9% 
saline or AAV9.CMV.HI.eGFP-Cre.WPRE.SV40 (Penn Vector Core, University of 
Pennsylvania).  
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RT-qPCR Confirmation of GluN2B-Deficiency 
Lumbar spinal cord tissue was collected in TRIzol® Reagent (phenol and 
guanidine isothiocyanate solution) in order to confirm the genotype of each 
subject.  Total RNA was extracted according to the manufacturer’s instructions. 
The RNA pellet was dissolved in nuclease-free water and RNA concentration 
was estimated by spectrophotometric analysis using the NanoDrop®ND-1000 
Spectrophotometer (Thermo Fisher Scientific).  An equal amount of RNA was 
used for each reaction. 
The expression levels of NMDA receptor subunits GluN2A and GluN2B 
were determined by estimating the messenger RNA copy number through 
quantitative real-time reverse transcription (RT)-PCR method.  All reactions were 
set up in 96-well format (Multiplate™ 96-Well PCR Plates, BIO-RAD) and carried 
out in CFX96 Touch™ Real-Time PCR Detection System (BIO-RAD) using 
iTaqTM Universal SYBR® Green One-Step Kit (BIO-RAD).  The oligonucleotide 
primers used were; Mouse GluN2A: F 5'-TCTATGACGCAGCCGTC TTGAACT-3' 
and R-5'-TGTGGTAGCAAAGATGTACC CGCT-3', GluN2B: F 5'-ATG 
AAGAGGGGCAAG GAGTT-3' and R 5'-CG ATG ATGGAGGAGACTTGG-3', 18S 
F 5'-AAGACGATCA GATACCGTCGTAG-3' and R 5'-TCCGTCAATTCCTTTAAG 
TTTCA-3' (Dhar and Wong-Riley 2009, Tajerian et al. 2015).  All reactions were 
run in triplicate. Each 20 µl of reaction mixture contained 10μl, 2X master mix, 
0.25 μl enzyme mix, 300nM of each primer, and 40ng of RNA. Two no template 
control (NTC) wells were included in each run.  Wells were sealed with optically 
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clear film. The PCR cycling conditions were 20 min at 50ºC, 1min at 95ºC and 
then 45 cycles each of denaturation at 95ºC for 10s and annealing and extension 
at 60ºC for 30s.  Melting curve analysis was performed to ensure the 
amplification of a single product in each reaction.  Amplification data were 
analyzed by CFX Manager software version 3.1 (BIO-RAD).  Data (Ct values) 
were analyzed using a comparative Ct method (ΔΔCt method (Schmittgen and 
Livak 2008).  Endogenous control, 18S was used; as it has been validated as a 
stable normalization gene for RT-qPCR (Piller, Decosterd and Suter 2013).  To 
obtain the ΔCt value for each of the sample the Ct value of 18S was subtracted 
from the Ct value of target (GluN2A/2B).  The ΔΔCt was obtained by using the 
ΔCt experimental value (AAV9-cre injected) minus the ΔCt control value (saline 
injected). Then the fold change (2−ΔΔCt) was calculated. 
 
Data Analysis  
All statistical analysis was considered significant at α = 0.05.  Mechanical 
paw withdrawal thresholds collected by von Frey filament stimulation were 
analyzed by repeated measures ANOVA with Bonferroni post-hoc corrected 
analysis.  Analysis of RT-qPCR was performed by normalizing the data to a 
housekeeping gene, 18S, and compared by unpaired Student’s t-test.  For 
induction of morphine tolerance, an unpaired Student’s t-test was performed on 
maximum possible effect (%MPE) between experimental and control groups.   
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Results 
Generation of Temporally- and Site-Restricted Reduction of GluN2B 
 At time of weaning (p21), Grin2B-floxed mice were intrathecally injected 
with either saline or AAV9-cre to generate wild type or GluN2B-deficient mice, 
respectively.  A minimum of two weeks following injection, lumbar spinal cord 
tissue was collected and analyzed by RT-qPCR for Grin2B and Grin2A 
expression in both wild type and GluN2B-deficient mice.  We observed a 
significant decrease in Grin2B, but not Grin2A, mRNA expression in lumbar 
spinal cord, as is represented in Figure 1.  
 
Agmatine Requires GluN2B-Containing NMDA Receptors to Attenuate 
Neuropathic Pain 
 The first aim of this study was to determine whether GluN2B is required for 
agmatine’s demonstrated reversal of pain behaviors.  Two GluN2B-floxed cohorts 
were run in parallel, one that had received an injection of saline at time of 
weaning (wild type) and another that received an injection of AAV9-cre at time of 
weaning (GluN2B KD) (Table 2).  A minimum of 4 weeks following this injection, 
every subject in both cohorts received spared nerve injury (SNI) to establish a 
state of chronic neuropathic pain.  All subjects were assessed for their von Frey 
thresholds prior to surgery and alternating days after surgery (days 1, 3, 5, and 7) 
on both the injured (ipsilateral) and non-injured (contralateral) hindpaws.  
Agmatine (10 nmol) or saline was delivered intrathecally prior to surgery and on 
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days 2, 4, and 6 post-surgery.  Additional von Frey testing continued weekly for a 
maximum of 30 days following injury, as is represented in Figure 2.  Following 
completion of behavioral testing, spinal cords were extracted and analyzed for 
GluN2A and GluN2B levels.  We observed that nerve-injury reduced pain 
thresholds in both GluN2B-deficient (Figure 2A) and wild type (Figure 2B) mice. 
During the induction phase (first post-operative week, intrathecal treatment of 
agmatine had little effect in either group.  During the maintenance phase (period 
of established chronic pain) agmatine demonstrated no effect in the GluN2B-
deficient mice whereas it reduced tactile hypersensitivity in the wild type mice, 
consistent with agmatine’s effects in ICR mice shown in Chapter 2.  These 
results suggest that the anti-hyperalgesic effects of agmatine require the GluN2B 
subunit of the NMDA receptor 
 
MK-801 Does Not Require the GluN2B Subunit of the NMDA Receptor to 
Reduce Neuropathic Pain Behavior  
 Based on agmatine’s lack of efficacy in GluN2B-deficient mice in the SNI 
model of neuropathic pain, we expanded this work to include additional, gold 
standard NMDA antagonists.  MK-801 is established to bind in the open channel 
of NMDA receptors (Huettner and Bean 1988, Wong et al. 1986), and as such 
should not require the presence of GluN2B in order to have efficacy in reversing 
pain behaviors.  Two GluN2B-floxed cohorts were run in parallel, one that 
received an i.t. injection of saline (wild type) at time of weaning and another that 
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received i.t. AAV9-cre (GluN2B-deficient) (Table 3).  All subjects were 
behaviorally assessed prior to SNI and days 1, 3, 5, and 7 following SNI (Figure 
3).  Following completion of behavioral testing, spinal cords were extracted and 
analyzed for Grin2A and Grin2B levels.  We observed moderate efficacy of MK-
801 in both the wild type and GluN2B-deficient mice at reversing long-term 
hypersensitivity following SNI.  We observed that, like agmatine, MK-801 had 
little effect in either GluN2B-deficient or wild type nerve-injured mice during the 
induction phase of tactile hypersensitivity.  However, during the maintenance 
phase, MK-801 demonstrated reduces tactile hypersensitivity in the GluN2B-
deficient mice even more robustly in the wild type mice.  These data suggest that, 
unlike agmatine, the GluN2B receptor subunit is not required for MK-801’s anti-
hyperalgesic effects in nerve-injured mice. 
 
Ifenprodil Requires GluN2B-Containing NMDA Receptors to Attenuate 
Neuropathic Pain 
 Ifenprodil has been demonstrated to be selective for the 2B subunit of the 
NMDA receptor (Gallagher et al. 1996, Chenard and Menniti 1999, Williams 
2001).  As such, we sought to parallel agmatine’s lack of efficacy in GluN2B-
deficient mice with ifenprodil.  Two GluN2B-floxed cohorts were run in parallel, 
one that had received an injection of saline at time of weaning (wild type) and 
another that received an injection of AAV9-cre at time of weaning (GluN2B KD) 
(Table 4).  A minimum of 4 weeks following this injection, every subject in both 
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cohorts received SNI to establish a state of chronic neuropathic pain.  All 
subjects were assessed for their von Frey thresholds prior to surgery and 
alternating days after surgery (days 1, 3, 5, and 7) on both the injured (ipsilateral) 
and non-injured (contralateral) hindpaws.  Additional von Frey testing continued 
weekly for a maximum of 30 days following injury (Figure 4).  Following 
completion of behavioral testing, spinal cords were extracted and analyzed for 
Grin2A and Grin2B levels.  We observed that, like in the agmatine and MK-801 
experiments, ifenprodil has no effect during the induction phase of tactile 
hypersensitivity.  Similar to agmatine, during the maintenance phase 
ifenprodil showed no effect in the GluN2B-deficient mice but did reduce tactile 
hypersensitivity in the wild type mice, consistent with ifenprodil’s effects in ICR 
mice shown in Chapter 2. 
 
Agmatine Requires the GluN2B Receptor Subunit to Prevent the 
Development of Morphine Analgesic Tolerance  
In addition to assessing the requirement of the GluN2B subunit for 
agmatine’s reduction of neuropathic pain, we studied the effects of GluN2B knock 
down on agmatine’s well established ability to prevent the development of spinal 
opioid tolerance.  We hypothesized that, like the requirement of GluN2B for 
agmatine’s inhibition of neuropathic pain, GluN2B would be required for 
agmatine’s effects on spinal opioid analgesic tolerance.  Chronic pain and opioid 
analgesic tolerance have long been known to share neuroplasticity-related 
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mechanisms based on NMDA-receptor activation (Mayer et al. 1999).  Two 
GluN2B-floxed cohorts were run in parallel, one that received a saline injection at 
time of weaning, and one that received AAV9-cre at time of weaning (Table 6).  A 
minimum of 4 weeks following this injection, subjects were injected daily with 
either morphine of morphine + agmatine and assessed for their tail-flick latencies 
(Table 5).  Following the 4th injection, mice were assessed for their tail flick 
latency and the percent efficacy was assessed (Figure 5).  In Figure 5A, the 
analgesic responses to morphine on day 1, 2, 3, and a final day 4 are displayed 
for subjects that received either the morphine tolerance-inducing dose or that 
same dose + agmatine.  It is clear that those that receive morphine progressively 
reduces analgesic efficacy by the third day whereas the group that received 
agmatine maintains analgesia at a constant level throughout the testing period. 
This pattern is consistent with prior studies demonstrating that agmatine protects 
against the development of morphine tolerance.  In contrast, in the GluN2B-
deficient mice (Figure 5B), both morphine-treated and morphine + agmatine 
treated mice demonstrate rapid and dramatic losses of morphine efficacy by Day 
3.  In this population, agmatine was ineffective.   The magnitude of tolerance 
induction was assessed for each treatment group and represented in Figure 5C 
where it is shown that in the WT mice the magnitude of tolerance development is 
greatly diminished in the “Morphine + Agmatine” group relative to “Morphine 
alone”; there is no difference in the magnitude of tolerance development in the 
GluN2B-deficient mice.  These data support the hypothesis that GluN2B is 
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required for the protective effect of agmatine in the development of opioid 
tolerance. 
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Figure 1 
 
Figure 1: Analysis of Grin2B reduction in GluN2B-floxed mice following AAV9-cre 
injection.  At time of weaning, subjects were injected with either saline control (WT) or 
AAV9-cre (KD).  A minimum of two weeks following injection, lumbar spinal cord was 
collected and analyzed by RT-qPCR for Grin2B and Grin2A mRNA expression.  
Unpaired Student’s t test, * represents significant difference from saline control p < 0.05.  
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Table 1: Study Timeline of NMDA-Mediated Inhibition of  
Maladaptive Neuroplasticity Following SNI 
Day -1 Day 0 Day 1 Day 2 Day 3 Day 4 
von Frey 
(vF) 
threshold 
baseline 
i.t. injection 
of 10 nmol 
study drug or 
saline 
  
SNI  
vF 
Threshold 
i.t. 10 
nmol 
study drug 
vF 
Threshold 
i.t. 10 nmol 
study drug 
Day 5 Day 6 Day 7 Day 26 Day 31 Day 32 
vF 
Threshold 
i.t. 10 nmol 
study drug 
vF 
Threshold 
vF 
Threshold 
vF 
Threshold 
Tissue 
extraction 
for mRNA 
analysis of 
Grin2B and 
Grin2A 
levels 
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Table 2: Study Composition of i.t. Agmatine  
or Saline Delivery Following SNI 
  Pre-Treatment i.t. 
Saline (4 weeks prior 
to experiment) 
Pre-Treatment i.t. 
AAV9-CMV-cre 
(4 weeks prior to 
experiment) 
i.t. 10 nmol Agmatine  9 mice (6 M, 3 F) 9 mice (6 M, 3 F) 
i.t. Saline   8 mice (8 M) 9 mice (7 M, 2 F) 
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Figure 2 
 
Figure 2: Intrathecal agmatine attenuates neuropathic pain responses in wild type, 
but not GluN2B-deficient mice.  Two cohorts (wild type control and GluN2B-deficient) were 
run in parallel.  All subjects were given spared nerve injury to induce local hypersensitivity.  
Immediately prior to surgery, subjects received saline control or 10 nmol agmatine, i.t. 
Subjects also received saline or agmatine on days 2, 4, and 6 following injury.  von Frey 
thresholds were taken prior to and following injury.  * represents significant difference from 
saline control. p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.  ANOVA with Bonferroni 
post-hoc analysis.  
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Table 3: Study Composition of i.t. MK-801  
or Saline Delivery Following SNI 
 
  Pre-Treatment i.t. 
Saline (4 weeks prior 
to experiment) 
Pre-Treatment i.t. 
AAV9-CMV-cre 
(4 weeks prior to 
experiment) 
i.t. 10 nmol MK-801  7 mice (5 M, 2 F)  10 mice (6 M, 4 F) 
i.t. Saline   8 mice (2 M, 6 F)  10 mice (8 M, 2 F) 
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Figure 3  
 
Figure 3: MK-01 attenuates neuropathic pain behaviors.  Two cohorts (wild type control and 
GluN2B-deficient) were run in parallel.  All subjects were given spared nerve injury to induce local 
hypersensitivity.  Immediately prior to surgery, subjects received saline control or 10 nmol MK-
801, i.t. Subjects also received saline or MK-801 on days 2, 4, and 6 following injury.  von Frey 
thresholds were taken prior to and following injury.  * represents significant difference from saline 
control. p < 0.05, ** p < 0.01, *** p < 0.001.  ANOVA with Bonferroni post-hoc analysis. 
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Table 4: Study Composition of i.t. Ifenprodil  
or Saline Delivery Following SNI 
  Pre-Treatment i.t. 
Saline (4 weeks prior 
to experiment) 
Pre-Treatment i.t. 
AAV9-CMV-cre 
(4 weeks prior to 
experiment) 
i.t. 10 nmol Ifenprodil 9 mice (5 M, 4 F) 9 mice (4 M, 5 F) 
i.t. Saline  9 mice (6 M, 3 F) 9 mice (4 M, 5 F) 
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Figure 4 
 
Figure 4: Intrathecal ifenprodil attenuates neuropathic pain responses in wild type, but not 
GluN2B-deficient mice.  Two cohorts (wild type control and GluN2B-deficient) were run in 
parallel. All subjects were given spared nerve injury to induce local hypersensitivity.  Immediately 
prior to surgery, subjects received saline control or 10 nmol ifenprodil, i.t..  Subjects also received 
saline or ifenprodil on days 2, 4, and 6 following injury.  von Frey thresholds were taken prior to 
and following injury.  * represents significant difference from saline control.  p < 0.05, ** p < 0.01, 
*** p < 0.001.  ANOVA with Bonferroni post-hoc analysis. 
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Table 5: Study Timeline of Morphine Tolerance in  
GluN2B-Deficient or Wild Type Mice 
Day 1 Day 2 Day 3  Day 4  Day 5 
AM: N/A AM: 10nmol 
i.t. MS or MS 
+ AG 
AM: 10nmol 
i.t. MS or MS 
+ AG 
AM: 10nmol 
i.t. MS or MS 
+ AG 
AM: Tissue 
extraction for 
confirmation 
of Grin2B 
knock down 
PM: Baseline 
Tail Flick  
  
10nmol i.t. 
morphine 
sulfate (MS) 
or morphine 
sulfate + 
agmatine  
(MS + AG) 
PM: 10nmol 
i.t. MS or MS 
+ AG 
 
Tail Flick 
PM: 10nmol 
i.t. MS or MS 
+ AG 
 
Tail Flick 
PM: 10nmol 
i.t. MS or MS 
+ AG 
 
Tail Flick 
  
 
 
 
 
 
 
 
 
 
 
 
	   116	  
Table 6: Study Composition of Agmatine Attenuation of Morphine 
Tolerance in Wild Type or GluN2B-Deficient Mice 
 
  
Pre-Treatment i.t. 
Saline (4 weeks prior 
to experiment) 
Pre-Treatment i.t. 
AAV9-CMV-cre 
(4 weeks prior to 
experiment) 
i.t. 10 nmol Morphine 
Sulfate 
8 mice (4 M, 4 F) 11 mice (4 M, 7 F) 
i.t. 10 nmol Morphine 
Sulfate + Agmatine  
8 mice (3 M, 5 F) 11 mice (6 M, 5 F) 
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Figure 5 
 
Figure 5: Agmatine attenuation of morphine tolerance in wild type but not GluN2B-
deficient mice.  Two cohorts (A – Wild Type control and B - GluN2B-Deficient) were run in 
parallel.  All subjects received either morphine or morphine + agmatine, i.t. twice daily for four 
days and were assessed for their tail flick latency prior to induction of tolerance and following 
daily morphine dosing.  C) The maximum percent effect (%MPE) was calculated for both day 1 
analgesic effects following morphine and day 4 analgesic effects following probe morphine.  This 
difference was calculated and is represented as delta %MPE.  Unpaired Student’s t test within 
group, * represents significant difference from the wild type morphine-only control p < 0.05.  
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Discussion 
 The first major finding of these studies was the development of a viable 
knock down of the GluN2B subunit of the NMDA receptor in lumbar spinal cord 
while avoiding the characterized side effects of a global knockout from birth.  
Figure 1 demonstrates the decrease in spinal GluN2B 4 weeks following the 
injection of AAV9-cre into GluN2B-floxed weanlings, leading to a temporally- and 
anatomically-restricted reduction.  
 We then tested the hypothesis that agmatine requires the 2B subunit of 
the NMDA receptor following intrathecal delivery, and that this interaction is 
responsible for agmatine’s efficacy in inhibiting the expression of neuropathic 
pain behaviors in vivo following spared nerve injury.  We utilized the same model 
of inhibition of maladaptive neuroplasticity described in Chapter 2 and compared 
agmatine’s efficacy at reducing the expression of neuropathic pain in wild type 
and GluN2B-deficient mice when given intrathecally immediately prior to spared 
nerve injury and alternating days following injury.  As is consistent with 
polyamines preferring GluN2B subunits of the NMDA receptor, agmatine was not 
efficacious at inhibiting the induction of pain behaviors in mice with lower levels of 
GluN2B as compared to wild type mice (Figure 2).  This effect persisted for a 
month following injury, at which time the lumbar spinal cord was harvested for 
confirmation of GluN2B deficiency.  
 In order to parallel our work described in Chapter 2, we conducted this 
study of inhibition of maladaptive neuroplasticity with ifenprodil in both GluN2B-
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deficient and wild type mice.  As was expected, intrathecally-delivered ifenprodil 
was unable to robustly inhibit the development of maladaptive neuroplasticity in 
GluN2B-deficient mice, but was efficacious in wild type controls (Figure 4).  
These results give strength to the hypothesis that agmatine, like ifenprodil, 
preferentially acts at GluN2B-containing NMDA receptors in the dorsal horn of 
the spinal cord.  We sought to perform another pharmacological control in this 
model using MK-801, a channel-blocker not reliant on the GluN2B subunit of the 
NMDA receptor, again as a parallel to the studies performed in Chapter 2, and 
found little appreciable difference between GluN2B-deficient and wild type 
controls.  
 The behavioral data presented here concerning agmatine’s protection 
from the development of morphine tolerance did reach significance in wild type, 
but not in GluN2B-deficient, mice (Figure 5).  This is indicative of agmatine 
requiring GluN2B containing NMDA receptors in order to inhibit the development 
of opioid tolerance.  This paradigm has been studied and published previously 
with the same experimenter and injector (Kitto and Fairbanks 2006) and has 
been repeated multiple times (Churchill 2014), but this is its first evaluation in 
GluN2B-deficient mice.  
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Summary and Conclusion 
 The data presented here support the hypothesis that agmatine 
preferentially acts at the GluN2B subunit of the NMDA receptor. 
Electrophysiological (Wataaja, in preparation), behavioral, and molecular data all 
support this mechanism of action.  Additionally, agmatine requires this subunit to 
inhibit maladaptive plasticity induced by chronic neuropathic pain or opioid 
tolerance.  This characteristic of agmatine makes it an attractive and viable 
candidate for translation to clinical use.  
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Chapter 5: Summary, Future Directions, and Conclusion 
 
Summary 
 The research described in this thesis has shown the efficacy of exogenous 
agmatine (Chapter 2) and gene therapy-induced increase of endogenous 
agmatine (Chapter 3) at reducing the expression of hypersensitivity via inhibition 
of the GluN2B subunit of the NMDA receptor (Chapter 4).  These findings 
indicate the value of development of agmatine therapy (whether exogenous 
delivery or gene therapy) for clinical application, including directly for relief of pain 
and indirectly as an opioid adjunct to prevent the development of opioid 
tolerance.  This work points to the necessity of understanding the long-term 
effects of gene therapy and elevated agmatine.  
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Conclusions 
Agmatine Clinical Safety and Efficacy 
Agmatine remains a novel and exciting prospective anti-hyperalgesic for 
chronic pain treatment due to its endogenous synthetic and degradative 
pathways, making its synthesis an attractive gene therapy target, as well as its 
current availability as a nutraceutical (Neis et al. 2017).  Long term safety studies 
of orally delivered agmatine have been completed in rats (Gilad and Gilad 2013) 
and humans (Gilad and Gilad 2014), including a randomized, double-blind, 
placebo-controlled trial of oral agmatine safety and efficacy in lumbar disc-
associated radiculopathy (Keynan et al. 2010).  In the dose escalation safety 
study, participants received 1.335 – 3.560 g/day over a period of 40-45 days and 
were interviewed 6 months after initiation of treatment to evaluate the safety of 
this regimen.  Three participants in the safety study reported mild-to-moderate 
diarrhea and nausea that ceased after agmatine was halted.  In the placebo-
controlled trial, agmatine was significantly more efficacious than placebo at 
relieving pain from lumbar disc herniation as measured by scores on the McGill 
Pain Questionnaire and the visual analog scale.  These data begin to establish 
the safety and efficacy of long-term agmatine use in a clinical population.  
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Future Directions 
Development and Analysis of Strategically-Substituted Agmatine (SSA) 
Compounds 
 Agmatine is a polyamine transmitter; it is rapidly metabolized in the 
periphery and has limited penetration into the central nervous system (CNS). 
Additionally, the half-life of agmatine given systemically is 30 minutes (Roberts et 
al. 2005).  The studies presented in this thesis utilized the intrathecal (i.t.) route of 
delivery in order to analyze exogenously delivered agmatine’s actions at the 
spinal cord, but a more accessible route of delivery must be considered for 
agmatine to be a clinically useful and relevant therapy.  To this end, we have 
previously developed and begun characterization of a line of strategically-
substituted agmatine (SSA) compounds designed to improve their penetration 
into the CNS and half-life, thus increasing their suitability for use as 
pharmacological agents.  We have begun testing these agents in models of 
peripheral hypersensitivity following nerve injury, respiratory depression, fear-
conditioned memory recall, and motor coordination.  We have also begun 
analyzing their pharmacokinetic profile compared to agmatine in order to identify 
promising SSAs for further analysis and translation.   
 
Agmatine Inhibition of Self-Administered Opioid Acquisition  
A pharmacological blockade of NMDA receptors has previously been 
shown to inhibit the acquisition of conditioned place preference (CPP), a model of 
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the early stages of addiction (Kalivas and Volkow 2011).  Agmatine has been 
demonstrated to inhibit the N-methyl-D-aspartate receptor without known side 
effects of NMDA inhibition including motor impairment and inhibition of learning 
and memory, as discussed in Chapter 2 and Chapter 3, making it a promising 
candidate for adjunct opioid therapy.  Previous work with agmatine and SSAs has 
shown the efficacy of these compounds in providing analgesia in various pain 
models including neuropathic and inflammatory pain (Yu et al. 2000, Fairbanks et 
al. 2000).  Agmatine has also been shown to be effective at attenuating the 
development of oral fentanyl self-administration (Wade et al. 2008).  However, 
because agmatine is a polyamine transmitter, it is rapidly metabolized in the 
periphery and has limited penetration into the CNS.  
In order to address this, we have begun using targeted injections of AAV 
vectors designed to express arginine decarboxylase (ADC), thus increasing 
endogenous agmatine in a sustained and site-specific manner at key points 
along the glutamatergic reward pathway.  We have also begun developing and 
characterizing a line of SSAs designed to improve their penetration into the CNS 
and their half-life, thus increasing their suitability for use as an inhibitor of opioid 
addiction acquisition following systemic injection.  We will test the hypothesis that 
agmatine is an effective inhibitor of the acquisition of oxycodone self-
administration using these two strategies.  Development of adjunct therapy to the 
delivery of traditional opioids allows continuation of use of well-characterized, 
clinically available analgesics such as fentanyl and oxycodone while attenuating 
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their addictive potential.  Through these studies, we aim to comprehensively 
characterize an adjunct therapy to maximize the analgesic potential of the most 
clinically relevant opioids while reducing potential side effects through dose 
reduction.   
 
Conclusion 
The National Institute of Medicine estimates that over 116 million Americans 
have or will experience chronic pain conditions in their lifetime (2016).  However, 
most clinically available pain therapeutics fail to adequately manage patient’s’ 
symptoms and doctors are wary to prescribe available opioid formulations due to 
concerns about diversion, misuse, addiction, and overdose (Kroenke and 
Cheville 2017).  The financial and societal impacts of chronic pain are 
monumental, with costs reaching over $635 billion per year in medical treatments 
and lost productivity.  We critically need new, non-opioid and opioid-adjunct 
therapies to safely relieve the burden of chronic pain from pain patients.  In this 
thesis I have described both small molecule and gene therapy approaches to 
managing chronic neuropathic pain.  While further development and testing is 
needed, it is hoped that the research presented here will further the goal of 
developing safe and effective therapeutics for pain patients.  
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